<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#" xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#" xmlns:Thesaurus="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>Hindawi Publishing Corporation <br /> Mediators In&#239;&#172;&#8218;ammation <br /> Volume 2014, Article ID 893634, 17 pages <br /> http://dx.doi.org/10.1155/2014/893634 <br />  <br />  <br />  <br />  <br /> Research Article <br /> The Acute Phase Trypanosoma cruzi Infection Is Attenuated <br /> in 5-Lipoxygenase-Deficient Mice <br />  <br />           Adriana M. C. Canavaci,1 Carlos A. Sorgi,1 Vicente P. Martins,2 Fabiana R. Morais,1 <br />           &#195;&#8240;rika V. G. Sousa,1 Bruno C. Trindade,1 Fernando Q. Cunha,3 Marcos A. Rossi,4 <br />           David M. Aronoff,5 L&#195;&#186;cia H. Faccioli,1 Auro Nomizo1 <br />           1 <br />             Departamento An&#194;&#180;alises Cl&#194;&#180;&#196;&#177;nicas, Toxicol&#194;&#180;ogicas e Bromatol&#194;&#180;ogicas, Faculdade Ci&#203;&#8224;encias Farmac&#203;&#8224;euticas Ribeir&#203;&#339;ao Preto, <br />             Universidade S&#203;&#339;ao Paulo, Avenida Caf&#194;&#180;e, s/n, 14040-903 Ribeir&#203;&#339;ao Preto, SP, Brazil <br />           2 <br />             Departamento Biologia Celular, Instituto Ci&#203;&#8224;encias Biol&#194;&#180;ogicas, Universidade Bras&#194;&#180;&#196;&#177;lia, Campus Darcy Ribeiro, <br />             70910-900 Bras&#194;&#180;&#196;&#177;lia, DF, Brazil <br />           3 <br />             Departamento Farmacologia, Faculdade Medicina Ribeir&#203;&#339;ao Preto, Universidade S&#203;&#339;ao Paulo, Avenida Bandeirantes, <br />             No. 3900, 14049-900 Ribeir&#203;&#339;ao Preto, SP, Brazil <br />           4 <br />             Departamento Patologia, Faculdade Medicina Ribeir&#203;&#339;ao Preto, Universidade S&#203;&#339;ao Paulo, Avenida Bandeirantes, <br />             No. 3900, 14049-900 Ribeir&#203;&#339;ao Preto, SP, Brazil <br />           5 <br />             Division Infectious Diseases, Department Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA <br />  <br />           Correspondence addressed Auro Nomizo; aunomizo@fcfrp.usp.br <br />  <br />           Received 4 April 2014; Revised 12 June 2014; Accepted 17 June 2014; Published 3 August 2014 <br />  <br />           Academic Editor: Marcelo T. Bozza <br />  <br />           Copyright &#194;&#169; 2014 Adriana M. C. Canavaci et al. This open access article distributed Creative Commons Attribution <br />           License, permits unrestricted use, distribution, reproduction medium, provided original work properly cited. <br />  <br />           In present work examine contribution 5-lipoxygenase- (5-LO-) derived lipid mediators immune responses during <br />           acute phase Trypanosoma cruzi infection 5-LO gene <span id='am-159' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-160' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-161' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-162' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-163' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-164' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-165' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-166' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-167' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-168' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-169' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-170' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-171' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-172' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-173' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-174' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-175' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-176' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-177' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-178' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-179' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-180' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-181' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-182' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-183' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-184' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-185' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-186' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-187' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-188' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-189' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-190' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-191' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-192' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-193' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-194' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-195' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-196' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-197' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-198' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-199' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-200' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-201' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-202' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-203' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-204' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-205' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-206' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-207' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-208' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-209' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-210' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-211' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-212' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-213' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-214' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-215' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-216' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-217' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-218' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-219' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-220' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-221' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-222' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-223' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-224' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-225' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-226' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-227' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-228' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-229' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-230' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-231' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-232' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-233' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-234' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-235' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-236' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span>knockout</span> (5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; ) mice wild-type (WT) mice. Compared with <br />           WT mice, 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice developed parasitemia/tissue parasitism, inflammatory cell infiltrates, lower mortality. <br />           This resistance 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice correlated differences immune response infection, including reduced PGE2 <br />           synthesis; sustained capacity splenocytes produce high levels interleukin (IL)-12 early infection; enhanced splenocyte <br />           production IL-1&#240;?&#8250;&#189;, IL-6, IFN-&#240;?&#8250;&#190;; rapid T-cell polarization secrete high quantities IFN-&#240;?&#8250;&#190; low quantities IL-10; and <br />           greater numbers CD8+ CD44high CD62Llow memory effector T cells end acute phase infection. The high mortality <br />           WT mice associated increased production LTB4 /LTC4 , T cell bias produce IFN-&#240;?&#8250;&#190;, high levels serum nitrite, <br />           marked protein extravasation peritoneal cavity, <span id='am-3' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-4' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-5' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-6' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-7' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-8' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-9' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-10' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-11' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-12' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-13' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-14' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-15' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-16' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-17' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-18' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-19' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-20' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-21' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-22' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-23' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-24' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-25' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-26' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-27' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-28' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-29' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-30' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-31' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-32' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-33' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-34' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-35' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-36' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-37' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-38' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-39' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-40' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-41' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-42' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-43' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-44' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-45' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-46' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-47' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-48' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-49' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-50' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-51' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-52' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-53' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-54' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-55' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-56' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-57' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-58' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-59' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-60' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-61' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-62' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-63' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-64' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-65' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-66' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-67' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-68' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-69' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-70' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-71' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-72' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-73' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-74' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-75' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-76' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-77' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-78' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-79' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-80' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span>survival</span> improved treatment cys-LT receptor 1 <br />           antagonist. These data provide evidence 5-LO-derived mediators negatively affect host survival acute phase of <br />           T. cruzi infection. <br />  <br />  <br />  <br />  <br /> 1. Introduction                                                            cytoplasm [2]. The acute phase disease is <br />                                                                            characterized marked increase parasite replication <br /> Infection Trypanosoma cruzi (T. cruzi), obligate intra-            migration blood, potentially leading systemic <br /> cellular protozoan parasite, causes American trypanosomia-                 infection. However, immunocompetent hosts able <span id='am-2' about='protege:TO' typeof='owl:Thing'>to</span> <br /> sis Chagas disease, zoonosis endemic Latin America.                generate innate inflammatory specific immune responses <br /> Approximately 60 million people live areas vector-                 acute secondary infection, controlling parasite <br /> borne transmission risk disease causes estimated                burden [3]. These responses primarily dependent on <br /> 14,000 deaths year [1]. After entering host, T. cruzi              cytokine/chemokine mediated activation infected phago- <br /> invades variety cell types, macrophages, heart                cytes and/or tissue cells leads intracellular killing <br /> muscle cells, skeletal muscle cells, neurons, replicating              [4], complete elimination parasite rarely <br />  2                                                                                                    Mediators Inflammation <br />  <br /> achieved. Parasite persistence tissues followed       5-LO pathway activity modulate the <br /> asymptomatic indeterminate phase, chronic chagasic         T. cruzi infection. To address issue, studied <br /> immunopathology develops approximately 25% cases            specifically acute phase T. cruzi infection 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; <br /> [5].                                                              mice. <br />      The factors governing immunological resistance acute <br /> trypanosomiasis fully understood. Host genetic back-      2. Materials Methods <br /> ground parasite strain differences relevant [6]. <br /> Early, partial control parasites infected tissue     2.1. Animals. Male mice (18&#226;&#8364;&#8220;20 g) used; 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; <br /> achieved local production type 1 IFNs [7], IL-1&#240;?&#8250;&#189; [8],       (129-Alox5tm1Fun /J) strain-matched WT mice (129-SF2/J) <br /> and &#240;?&#8250;&#189;-chemokines [9]. Therefore, effective parasite control       purchased Jackson Laboratories (Bar Harbor, ME). <br /> likely requires participation innate adaptive     The animal colony bred maintained specific <br /> immune cells including macrophages, dendritic cells, NK       pathogen-free conditions Faculdade Ci&#203;&#8224;encias Far- <br /> cells secrete proinflammatory cytokines (e.g., IL-12      mac&#203;&#8224;euticas Ribeir&#203;&#339;ao Preto (Universidade S&#203;&#339;ao Paulo, <br /> IFN-&#240;?&#8250;&#190;) [10] naive T cells generation parasite-     Brazil). This study approved carried strict <br /> specific CD4+ CD8+ effector T cells [11], produce       accordance guidelines Animal Care Commit- <br /> Th1 cytokines IFN-&#240;?&#8250;&#190; and, lesser quantities, Th2        tee Universidade S&#203;&#339;ao Paulo Biosafety Com- <br /> cytokines IL-4 IL-10 [12, 13].                        mittees (Process nos. 05.1.592.53.2 CQB-0019/97). All <br />      Although immune functions assigned                 euthanasia performed CO2 /O2 excess atmosphere, <br /> to number polypeptide mediators (cytokines               efforts minimize suffering. <br /> chemokines) host defense T. cruzi, little attention <br /> has paid role lipid mediators. These lipid <br />                                                                   2.2. Parasite Infection Pharmacological Treatment. Mice <br /> molecules mainly eicosanoids generated through <br />                                                                   infected intraperitoneally 200 units blood <br /> the effects cyclooxygenases (COX) 5-lipoxygenase <br />                                                                   form T. cruzi (Colombian strain) 0.2 mL 0.15 M PBS. <br /> (5-LO) play variety roles regulating host innate <br />                                                                   Control mice received volume sterile PBS. Par- <br /> and adaptive immune responses [14]. The 5-LO pathway <br />                                                                   asites counted 5 &#240;?&#339;&#8225;L blood previously described <br /> leads formation biologically relevant classes <br />                                                                   [32]. WT mice previously subjected T. cruzi infection <br /> of leukotrienes (LTs): non-cysteinyl LTs LTB4 ; and <br />                                                                   [33]. In experiments, infected WT mice treated <br /> cysteinyl-LTs (cys-LTs) LTC4 , LTD4 , LTE4 [15]; <br />                                                                   cys-LT receptor 1 antagonist, montelukast (10 mg/kg, <br /> and activity 5-LO common step LXA4 <br />                                                                   Singulair; Merck Sharp &amp; Dohme, Campinas, Brazil) or <br /> synthesis [16]. LTs established play protective <br />                                                                   vehicle, carboxymethylcellulose (0.5% w/v), administered <br /> roles infection microbial pathogens, <br />                                                                   orally gavage (300 &#240;?&#339;&#8225;L/animal) postinoculation days <br /> including Salmonella typhimurium, Pseudomonas aeruginosa <br />                                                                   14&#226;&#8364;&#8220;32, starting day 14 given 2 days. T. cruzi <br /> [17], Klebsiella pneumoniae [18], vesicular stomatitis <br />                                                                   soluble antigens obtained trypomastigote forms <br /> virus encephalitis [19], Histoplasma capsulatum [20]. <br />                                                                   (Colombian strain) used vitro experiments [32]. <br /> However, settings 5-LO products shown <br />                                                                   Briefly, trypomastigotes washed twice cold PBS, <br /> to play contradictory roles, example, Mycobacterium <br />                                                                   subjected freeze-thaw cycles, centrifuged (9000 &#195;&#8212;g, <br /> tuberculosis infection models [21, 22]. In addition, cecal <br />                                                                   10 min, 4&#226;&#710;&#732; C). The supernatant filtered 0.22 &#240;?&#339;&#8225;m <br /> ligation puncture model peritonitis, LTs exhibited <br />                                                                   pore size membrane filter, protein concentration was <br /> beneficial effects local immunity exhibited deleterious <br />                                                                   measured using colorimetric assay (Pierce, Rockford, IL). <br /> effects hemodynamic responses [23]. Immunoregulatory <br /> lipids, arachidonic acid-derived eicosanoids, <br /> are increasingly implicated pathogenesis parasitic      2.3. Histology Quantitative Tissue Parasite Nest Determi- <br /> infections [24, 25]. The 5-LO pathway products               nation. Histology tissue parasite counts performed <br /> also implicated modulating pathogenesis               described [11]. Briefly, tissue samples fixed <br /> of parasitic infections results         4% buffered formalin processed conventional <br /> been contradictory. In vitro, LTB4 LTC4 potentiate            paraffin embedding day 16 infection. Sections (8 &#240;?&#339;&#8225;m) <br /> macrophages kill T. cruzi [26, 27] Leishmania              deparaffinized stained hematoxylin eosin. <br /> amazonensis [28]. However, mediators              Intact parasite nests evaluated blinded samples by <br /> implicated conferring susceptibility Schistosoma            counting number parasites nests 100 microscopic <br /> mansoni [29], Strongyloides venezuelensis [30], cerebral      fields/sample nonconsecutive sections. <br /> malaria [31], suggesting LTs play conflicting <br /> roles parasite infection.                                  2.4. Eicosanoid Levels Peritoneal Cell Supernatants. Peri- <br />      The immunoregulatory effects 5-LO pathway                 toneal cells collected intraperitoneal injection 4 mL <br /> eicosanoids complex context dependent. While              cold PBS uninfected controls, infected WT, 5- <br /> their net effects beneficial host defense     LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice various time points infection. Cell concen- <br /> microbial pathogens, necessarily true         tration adjusted 106 cells mL&#226;&#710;&#8217;1 Hank&#226;&#8364;&#8482;s buffered salt <br /> infections. In light importance regulating immune       solution (HBSS; Sigma, St. Louis, MO) Ca+2 Mg+2 . <br /> responses parasitic infections, contrasting roles      Cells stimulated 0.5 &#240;?&#339;&#8225;M calcium ionophore <br /> exhibited LTs infection models, asked            A23187 (Sigma, Saint Louis, EUA) 15 min 37&#226;&#710;&#732; C a <br />  Mediators Inflammation                                                                                                       3 <br />  <br /> humidified atmosphere 5% CO2 . The supernatants            2.9. Protein Extravasation. Protein extravasation as- <br /> harvested PGE2 , LTB4 , LTC4 levels determined        sessed previously described [23]. Control mice infected <br /> by specific EIA kit, following manufacturer&#226;&#8364;&#8482;s instructions     mice i.v. injected Evans blue dye (50 mg/kg in <br /> (GE Healthcare, Little Chalfont, UK).                              volume 0.1 mL; Sigma, Saint Louis, EUA). After 1 h, <br />                                                                    mice euthanized CO2 inhalation, peritoneal <br />                                                                    exudates recovered injecting 2 mL PBS. The peri- <br /> 2.5. Spleen Cell Culture. Mice experimental groups <br />                                                                    toneal exudates centrifuged 10 min 200 &#195;&#8212;g, the <br /> were euthanized various days inoculation. Single-cell <br />                                                                    supernatant saved colorimetric determinations. The <br /> suspensions prepared passing spleen through <br />                                                                    OD determined 630 nm automated microplate <br /> a 70 &#240;?&#339;&#8225;m cell strainer (Falcon, Sollentuna, Sweden). The <br />                                                                    reader. <br /> splenocytes washed 3 times HBSS, counted with <br /> a hemocytometer, assessed viability, suspended in <br /> RPMI 1640 medium supplemented 10% FCS, peni- <br />                                                                    2.10. In Vitro Macrophage Infection. Peritoneal cells WT <br /> cillin (100 U/mL), streptomycin (100 &#240;?&#339;&#8225;g/mL), gentamicin <br /> (50 &#240;?&#339;&#8225;g/mL) (Gibco-Invitrogen, Carlsbad, CA) HBSS sup-           5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice collected, washed twice, counted <br /> plemented 5% FCS. The cell concentration adjusted         cell concentration adjusted 106 cells/mL in <br /> to 107 cells/mL cultured 24-well plates (Nalge Nunc,        supplemented RPMI medium. Cells attached 13 mm- <br /> Rochester, NY) 1 mL supplemented RPMI medium,           diameter glass coverslips placed 24-well plates (Nalge <br /> 5 &#240;?&#339;&#8225;g anti-CD3&#240;?&#339;&#8364; 10&#226;&#8364;&#8220;50 &#240;?&#339;&#8225;g soluble T. cruzi antigens    Nunc, Rochester, NY), 90 min 37&#226;&#710;&#732; C atmosphere of <br /> at 37&#226;&#710;&#732; C atmosphere 5% CO2 24&#226;&#8364;&#8220;48 h. Supernatants      5% CO2 . The nonadherent cells removed washings in <br /> were collected stored &#226;&#710;&#8217;70&#226;&#710;&#732; C use.               warm supplemented RPMI medium. Peritoneal macrophages <br />                                                                    (PM) isolated procedure &gt;90% pure measured <br />                                                                    staining F4/80+ (data shown). The PMs were <br /> 2.6. Metabolic Assays. Splenocytes (4 &#195;&#8212; 105 cell/well)        stimulated 6 h 5 ng/mL IFN-&#240;?&#8250;&#190; (BD Pharmingen, <br /> different experimental groups cultured quintuplicate       San Diego, CA) plus 0.1 &#240;?&#339;&#8225;g/mL LPS Escherichia coli <br /> in flat 96-well microplates (Nalge Nunc, Rochester, NY)       (Sigma, Saint Louis, EUA) infected parasite-to- <br /> supplemented RPMI medium. Cells cultured             macrophage ratio 5 : 1/well. After 2 h, glass coverslips <br /> with anti-CD3&#240;?&#339;&#8364; IgG (1 &#240;?&#339;&#8225;g/mL; BD Pharmingen, San Diego,             washed times PBS remove free parasites, fixed <br /> CA) 37&#226;&#710;&#732; C humidified atmosphere 5% CO2 . After          absolute methanol, stained Panoptic stain (Labor- <br /> 60 h, 10 &#240;?&#339;&#8225;L (5 mg/mL) MTT (Sigma, Saint Louis, EUA)         clin, Pinhais, Brazil), dried, mounted glass slides, and <br /> added well, cells incubated additional     examined microscopically association (parasite adhered <br /> 4 h, followed addition 50 &#240;?&#339;&#8225;L 20% SDS PBS           macrophages plus internalized parasites) previously <br /> and stored dark overnight. Absorbance measured          described [26]. For killing assay, noninternalized parasites <br /> at 570 nm using automated microplate reader (&#240;?&#339;&#8225;QUANT;            infected macrophages wells removed 24 h later by <br /> BioTek Instruments, Winooski, VT).                                 gentle washes warm supplemented RPMI medium. <br />                                                                    Fresh supplemented RPMI medium added each <br /> 2.7. Flow Cytometry. Spleen cells isolated described       well, infected macrophages cultured 37&#226;&#710;&#732; C, in <br /> above placed ice-cold PBS supplemented 5% FCS          atmosphere 5% CO2 10 days, 50% the <br /> and 0.1% sodium azide. Staining performed previ-            medium removed replaced volume <br /> ously described [11]. The following fluorochrome-conjugated        supplemented RPMI medium 48 h. After 7&#226;&#8364;&#8220;11 days <br /> monoclonal antibodies used: anti-CD4 [H129.19]; anti-         infection, culture supernatants collected daily to <br /> CD8 [53-6.7]; anti-CD19 [MB19-1]; anti-CD25 [7D4]; anti-           count number motile trypomastigotes/well. <br /> CD44 [IM7]; anti-CD69 [H1.2F3]; anti-Gr-1/Ly6C/Ly6G <br /> [RB6-8C5]; anti-CD45RB [16A]; anti-CD62L [MEL-14]; anti- <br /> CD11b [M1/70] (BD Pharmingen, San Diego, CA); anti-            2.11. Nitrite/Nitrate Concentration. Tail-vein blood samples <br /> CD11c [HL3]&#226;&#8364;&#8221;(Serotech, Raleigh, NC) anti-F4/80 [CI:A3-             obtained day 22 inoculation. Nitrate serum <br /> 1] anti-GITR [DTA-1] (eBioscience, San Diego, CA).             samples converted nitrite nitrate reductase, and <br /> After staining, cells fixed 1% paraformaldehyde      serum levels nitrate/nitrite (Nitric oxide end-products or <br /> in PBS analyzed using FACSCanto (BD Biosciences,             metabolites) measured absorbance using Griess <br /> San Jose, CA), 50,000 events/sample recorded. Data            Reaction (Calbiochem, La Jolla, CA) [34]. The OD was <br /> processed using FlowJo software (FlowJo LLC, Ashland, OR).         determined 540 nm &#240;?&#339;&#8225;QUANT automated microplate <br /> Cell numbers calculated using percentage obtained         reader. The nitriteconcentration determined reference <br /> by FACS analysis total numbers leukocytes counted       standard (1&#226;&#8364;&#8220;100 &#240;?&#339;&#8225;M) sodium nitrite curve. <br /> in hemocytometer. <br />                                                                    2.12. Cytokine ELISA. Levels IL-1&#240;?&#8250;&#189;, IL-2, IL-6, IL-10, IL- <br /> 2.8. T. cruzi-Specific Antibodies. Specific IgG, IgG1, IgG2a   12, TNF-&#240;?&#8250;&#188;, IFN-&#240;?&#8250;&#190; quantified ELISA according to <br /> were determined mouse sera ELISA previously               manufacturer&#226;&#8364;&#8482;s instructions (BD Pharmingen, San Diego, <br /> described [32]. The individual titers considered          CA) splenocytes culture supernatant. The lower limits <br /> highest serum dilutions presented OD492 &gt; 0.1.                detection cytokines 9.4 pg/mL. <br />  4                                                                                                     Mediators Inflammation <br />  <br /> 2.13. Statistical Analysis. The results presented means     infiltrates WT mice (Figure 2(c)) 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice <br /> &#194;&#177; SD, exception parasitemia, shown        (Figure 2(d)). <br /> means &#194;&#177; SEM. The tests used evaluate differences <br /> among groups mentioned figure legends. Values        3.4. Cytokine Production Spleen Cells. In culture, the <br /> &#240;?&#8216;&#402; &lt; 0.05 considered significant.                              spleen cells infected mice spontaneously produced IL-1&#240;?&#8250;&#189;, <br />                                                                    IL-6, TNF-&#240;?&#8250;&#188;, IL-10, IL-12, IFN-&#240;?&#8250;&#190; (Figure 3). It notable <br />                                                                    production of cytokines greater <br /> 3. Results                                                         weeks infection, peaking day 12 after <br /> 3.1. Lipid Mediator Production Infected Peritoneal Cells.       inoculation, correlating parasitemia (Figure 1(c)). In <br /> Peritoneal cells T. cruzi-infected mice (WT) released         general, production IL-6, IL-12, IFN-&#240;?&#8250;&#190; greater <br /> significantly LTB4 PGE2 calcium ionophore            spleen cells infected 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; WT cells. On day <br /> stimulation did cells obtained uninfected mice           5, production IL-1&#240;?&#8250;&#189;, IL-6, IL-12, IFN-&#240;?&#8250;&#190; higher <br /> (Figures 1(a) 1(b)). The potential cells produce LTB4    5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; cells WT cells TNF-&#240;?&#8250;&#188; production <br /> was elevated early time point inoculation (day 5)      lower. On day 12, IL-1&#240;?&#8250;&#189; levels comparably high in <br /> and increased gradually infection, peaking       cell cultures mouse strains, spleen cells <span id='am-1' about='protege:FROM' typeof='owl:Thing'>from</span> <br /> day 19. This potential decreased drastically       infected 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; showed significantly greater production of <br /> late phase acute infection (day 26; Figure 1(a)).               IL-6, IL-12, IFN-&#240;?&#8250;&#190;, TNF-&#240;?&#8250;&#188; compared infected WT <br />      The potential peritoneal cells T. cruzi-infected      cells. The production IL-10 showed opposite trend <br /> mice produce PGE2 increased (Figure 1(b)).             (Figure 3(d)). In late phase infection (on days 19 and <br /> Peritoneal cells infected WT mice released PGE2 early      26), 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; spleen cells, contrast observed <br /> time points (day 5) increased markedly subsequent           WT spleen cells, showed sustained elevation the <br /> days, peaking day 12. PGE2 levels decreased drastically         production IL-1&#240;?&#8250;&#189; (Figure 3(a)) IL-10 (Figure 3(d)), <br /> by day 19 increased late phase             higher levels IL-12 (Figure 3(e)), lower levels IFN-&#240;?&#8250;&#190; <br /> acute infection day 26. Peritoneal cells infected 5-       (Figure 3(f)). <br /> LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice showed enhanced production PGE2 <br /> (Figure 1(b)) <span id='am-315' about='xsp:pattern' typeof='owl:Thing'>pattern</span> different observed      3.5. Cell Populations Spleen Infected Mice. Infection <br /> WT cells did suggest shunting arachidonic acid          mice T. cruzi led accumulation Gr1+ <br /> towards cyclooxygenase pathway. PGE2 production 5-          cells (i.e., neutrophils), Gr1+ /CD11c+ cells (i.e., plasmacytoid <br /> LO&#226;&#710;&#8217;/&#226;&#710;&#8217; cells elevated day 5 increased day         dendritic cells), CD11b+ cells (i.e., myeloid lineage cells), <br /> 12 (albeit levels WT) level maintained      F4/80+ cells (i.e., macrophages) spleens when <br /> throughout infection. Notably, peritoneal cells      compared uninfected control mice (Figures 4(a)&#226;&#8364;&#8220;4(d)). <br /> WT 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; T. cruzi-infected mice appeared produce          Greater numbers Gr1+ , Gr1+ /CD11c+ , CD11b+ , F4/80+ <br /> more PGs LTs, evidenced fact LTB4 levels       cells present 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; WT spleens day <br /> (Figure 1(a)) far lower PGE2 (Figure 1(b)).     12 infection (Figures 4(a)&#226;&#8364;&#8220;4(c)). Macrophage (F4/80+ ) <br />                                                                    numbers higher spleens 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice day 19 <br />                                                                    infection compared WT mice (Figure 4(d)). <br />                                                                    In addition, day 5 infection, plasmacytoid dendritic <br /> 3.2. Control Parasite Dissemination Host Survival after <br />                                                                    cell (Gr1+ /CD11c+ ) counts higher infected 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; <br /> Infection. As shown Figure 1(c), infected 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice          mice, compared infected WT mice (Figure 4(b)). <br /> presented delay appearance blood-circulating           It notable myeloid lineage cells numbers higher <br /> parasites low parasite numbers second peak      spleens infected WT animals spleens 5- <br /> parasitaemia compared WT mice. In addition, number <br />                                                                    LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice (Figure 4(c)). <br /> of intact parasite nests heart muscle tissue considerably <br /> lower 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice (Figure 1(d)). Furthermore,            3.6. Peritoneal Macrophage Infection. In infected 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; <br /> 17% 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice died postinoculation days 16&#226;&#8364;&#8220;           mice, PMs IFN-&#240;?&#8250;&#190; increased (Figures 4(d) and <br /> 19, WT mice did begin die day 19              3(f)). The vitro infection peritoneal LPS-plus IFN-&#240;?&#8250;&#190;- <br /> (Figure 1(e)). In acute phase infection, 30%        activated-macrophages WT 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice showed <br /> WT mice capable surviving infection. In contrast,      differences association macrophages parasites <br /> 82.3% 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice controlled parasite efficiently          (binding internalization) ability kill <br /> survived acute phase infection (Figure 1(e)).               intracellular parasites (Figures 4(e) 4(f)). Compared with <br />                                                                    activated PMs WT mice, 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice <br /> 3.3. Inflammatory Infiltrate Tissue Parasitism      presented greater capacity associate blood form <br /> Acute Phase T. cruzi Infection. Analysis histological    parasite, evidenced higher numbers bound <br /> samples heart muscle tissue collected 16 days       internalized parasites (Figure 4(e)). Activated PMs from <br /> inoculation revealed WT mice presented intact            5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice efficient killing internalized <br /> parasite nests amastigote forms              parasites, evidenced lower numbers parasites <br /> nests (Figure 2(a)) did 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice (Figure 2(b)). In        recovered vitro infection compared WT PMs <br /> addition, greater inflammatory mononuclear cell         (Figure 4(f)). <br />  Mediators Inflammation                                                                                                                                                                                                      5 <br />  <br />  <br />                                      160                                                            &#226;&#710;&#8212;                                                              25000 <br />                                                                                                                                                                                                  &#226;&#710;&#8212; <br />  <br />                                                                                                                                                                    20000 <br />                                      120 <br />  <br />  <br />  <br />  <br />                                                                                                                             PGE2 (pg/mL) <br />             LTB4 (pg/mL) <br />  <br />  <br />  <br />                                                                      &#226;&#710;&#8212;                                                                                             15000 <br />                                             80                                                                                                                                                                         &#226;&#710;&#8212; <br />                                                                                                                                                                    10000                                                   # <br />                                                         &#226;&#710;&#8212;                                                                                                                                             #           #        &#226;&#710;&#8212; <br />                                                                                                                                                                                    &#226;&#710;&#8212;                  &#226;&#710;&#8212;           &#226;&#710;&#8212; <br />                                             40                                                                    &#226;&#710;&#8212; <br />                                                                                                                                                                     5000 <br />                                                                            #                                                                                                           #                    &#226;&#710;&#8212; <br />                                                             #                                                         #                                                                &#226;&#710;&#8212; <br />                                                                                                         # <br />                                              0                                                                                                                           0 <br />                                                        5          12             19                             26                                                             5            12             19         26 <br />                                                                  Days infection                                                                                                      Days infection <br />  <br />                                                       WT                                            WT infected                                                               WT                           WT infected <br />                                                       5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217;                                       5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; infected                                                          5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217;                      5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; infected <br />  <br />                                                                      (a)                                                                                                                        (b) <br />                                                   6 <br />                                             &#195;&#8212;10 <br />                                             2.0 <br />                                                                                                                                                                    150 <br />                                                                                                                                 Number parasites nests/100 mf <br />                  Number parasites (mL) <br />  <br />  <br />  <br />  <br />                                             1.5 <br />  <br />                                                                                                                                                                    100 <br />                                             1.0 <br />  <br />  <br />                                             0.5                                                                                                                     50 <br />                                                                  #                             # # # <br />                                                                                                      # <br />                                              0                                                                                                                                                                    # <br />                                                   0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 <br />                                                                                                                                                                      0 <br />                                                                  Days infection <br />  <br />                                                        WT                                                                                                                    WT <br />                                                        5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217;                                                                                                               5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; <br />                                                                       (c)                                                                                                                       (d) <br />                                                                                               100 <br />                                                                                                90                                                                                  P &lt; 0.0001 <br />                                                                                                80 <br />                                                                                                70 <br />                                                                                Survival (%) <br />  <br />  <br />  <br />  <br />                                                                                                60 <br />                                                                                                50 <br />                                                                                                40 <br />                                                                                                30 <br />                                                                                                20 <br />                                                                                                10 <br />                                                                                                 0 <br />                                                                                                     0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 <br />                                                                                                                Days infection <br />                                                                                                             WT <br />                                                                                                             5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; <br />                                                                                                                           (e) <br />  <br /> Figure 1: Lipid mediator production, parasitemia, tissue parasitism, survival rate WT 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice infected T. cruzi: ((a) and <br /> (b)) LTB4 PGE2 : peritoneal cells collected control, infected WT, infected 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice (&#240;?&#8216;&#8250; = 10/group) stimulated with <br /> calcium ionophore. &#226;&#710;&#8212; &#240;?&#8216;&#402; &lt; 0.01 versus uninfected group; # &#240;?&#8216;&#402; &lt; 0.01 versus WT infected mice. (c) Parasitemia (&#240;?&#8216;&#8250; = 10 mice/group). # &#240;?&#8216;&#402; &lt; 0.001 <br /> versus infected WT mice. (d) Parasite nests heart tissue postinoculation day 16. &#226;&#710;&#8212; &#240;?&#8216;&#402; &lt; 0.001 versus infected WT mice. (e) Survival: WT <br /> mice (squares) 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice (triangles), &#240;?&#8216;&#8250; = 10 animals/group. Wilcoxon signed-rank test (level significance, &#240;?&#8216;&#402; &lt; 0.001). Data are <br /> representative independent experiments. <br />  6                                                                                                           Mediators Inflammation <br />  <br />                                              WT                                           5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; <br />  <br />  <br />  <br />  <br />                     Parasite nests <br />  <br />  <br />  <br />  <br />                                              (a)                                             (b) <br />                    Inflammatory infiltrate <br />  <br />  <br />  <br />  <br />                                              (c)                                             (d) <br />  <br /> Figure 2: Histopathological analysis heart tissue parasitism inflammatory infiltrate T. cruzi-infected WT 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice <br /> (&#240;?&#8216;&#8250; = 8/group) postinoculation day 16 (staining H&amp;E; magnification, &#195;&#8212;200): (a) section WT mouse, showing numerous large <br /> amastigote nests, (b) section 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mouse, showing fewer, smaller nests, (c) section WT mouse, showing intense mononuclear <br /> cell infiltration, (d) section 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mouse, showing infiltration. Photomicrographs experiment representative of <br /> three independent experiments. <br />  <br />  <br />  <br /> 3.7. Spleen B-Cell Counts Serum Levels Parasite-Specific        WT 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; infected mice. In infected mice, majority <br /> Immunoglobulins. As shown Figure 5(a), splenic CD19+ B-             splenic T-cell populations presented full/late T-cell <br /> cell counts greater mice infected T. cruzi           activation markers CD4+ CD44+ CD8+ CD44+ (Figures <br /> in control mice. On day 5 inoculation, splenic CD19+             6(c) 6(d)). On day 5 inoculation, numbers of <br /> cell counts elevated infected WT mice gradually            T-cell phenotypes elevated infected WT mice, <br /> returned baseline values end acute phase           gradually increasing course infection peaking <br /> infection. In contrast, splenic CD19+ cell counts increased            day 26, study endpoint (Figure 6). In contrast, infected <br /> significantly infected 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice       5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice presented delayed elevation T-cell counts, <br /> weeks infection, gradually significantly              increase of activated T-cell phenotypes <br /> elevated WT mice later phase infection.                 pronounced observed WT spleens. Infected <br />      Mice infected T. cruzi produced detectable levels         5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice presented significant increase CD4+ CD44+ <br /> parasite-specific IgG antibodies time-dependent manner            CD8+ CD44+ counts day 12, marked increase the <br /> during later phase infection (Figure 5(b)). The principal       CD4+ CD69+ count day 19, slight significant <br /> isotype produced infection IgG2a, levels             increase CD8+ CD69+ CD4+ CD25+ counts day <br /> IgG1 low. Compared WT mice, 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice                     26. <br /> presented lower levels parasite-specific IgG day 26, <br /> as parasite-specific IgG2a days 19 26             3.9. T-Cells Properties, Cytokine Production, CD4+ Mem- <br /> infection. <br />                                                                        ory T Cells Expressing CD45RB&#240;?&#8216;&#8482;&#240;?&#8216;&#339;&#240;?&#8216;&#164; CD44&#226;&#8222;&#381;&#240;?&#8216;&#8211;&#240;?&#8216;&#8221;&#226;&#8222;&#381; CD62L&#240;?&#8216;&#8482;&#240;?&#8216;&#339;&#240;?&#8216;&#164; in <br />                                                                        Spleen. As shown Figure 7(a), spleen cells from <br /> 3.8. T-Cell Phenotypes Spleens Infected Mice. As indi-       control mice proliferated stimulation anti-CD3&#240;?&#339;&#8364;, <br /> cated Figure 6, infected mice presented elevated CD4+           expected, spleen cells collected infected <br /> CD8+ T-cell counts, markers CD4+ CD69+ , CD8+ CD69+ ,              WT mice day 12 inoculation stimulated with <br /> CD4+ CD25+ , CD4+ CD44+ , CD8+ CD44+ , indi-                 anti-CD3&#240;?&#339;&#8364; presented dramatic reduction proliferation. <br /> cate presence activated T-cells spleens          However, spleen cells infected 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice day 12 <br />  Mediators Inflammation                                                                                                                                                         7 <br />  <br />  <br />  <br />  <br />                                150                         IL-1&#240;?&#8250;&#189;                                            250                                 IL-6 <br />  <br />                                                            &#226;&#710;&#8212;                                                                                    # <br />                                125                                                                                                              &#226;&#710;&#8212; <br />                                                      &#226;&#710;&#8212;                                                      200 <br />                                100 <br />                IL-1&#240;?&#8250;&#189; (pg/mL) <br />  <br />  <br />  <br />  <br />                                                                                              IL-6 (pg/mL) <br />                                                                                                             150                          &#226;&#710;&#8212; <br />                                 75 <br />                                                                          #                                  100               # <br />                                 50                                                    #                                       &#226;&#710;&#8212; <br />                                               #                          &#226;&#710;&#8212;            &#226;&#710;&#8212; <br />                                               &#226;&#710;&#8212; <br />                                 25                                                                           50 <br />  <br />                                  0                                                                            0 <br />                                       5            12               19           26                                   5                12               19           26 <br />                                                   Days infection                                                                Days infection <br />                                                      (a)                                                                                 (b) <br />                                                                                                                                           IL-10 <br />                                120                         TNF-&#240;?&#8250;&#188;                                            250                          # <br />                                           &#226;&#710;&#8212;                                                                                              &#226;&#710;&#8212; <br />  <br />                                                                                                             200 <br />                                 90 <br />                TNF-&#240;?&#8250;&#188; (pg/mL) <br />  <br />  <br />  <br />  <br />                                                                                            IL-10 (pg/mL) <br />  <br />  <br />                                                                                                             150 <br />                                                                                                                           &#226;&#710;&#8212; &#226;&#710;&#8212;                   # <br />                                 60                                                                                                              &#226;&#710;&#8212; <br />                                               #           # <br />                                               &#226;&#710;&#8212;           &#226;&#710;&#8212;                                                 100                                                               # <br />                                                                                                                                                                  #            &#226;&#710;&#8212; <br />                                                                                                                                                                  &#226;&#710;&#8212; <br />                                 30 <br />                                                                                                             50 <br />  <br />  <br />                                  0                                                                            0 <br />                                       5            12             19            26                                    5                12               19           26 <br />                                                   Days infection                                                                Days infection <br />                                                      (c)                                                                                 (d) <br />                                                            IL-12                                                                            IFN-&#240;?&#8250;&#190; <br />                           1000                                                                              2500 <br />                                                                                       #                                                             # <br />                                                                                       &#226;&#710;&#8212;                                                             &#226;&#710;&#8212; <br />                                                                          #                                  2000 <br />                                                                          &#226;&#710;&#8212; <br />                                750 <br />         IL-12 (pg/mL) <br />  <br />  <br />  <br />  <br />                                                                                           IFN- &#240;?&#8250;&#190; (pg/mL) <br />  <br />  <br />  <br />  <br />                                                                                                             1500 <br />                                                                      &#226;&#710;&#8212;                                                            #                          &#226;&#710;&#8212; <br />                                500                         #                                                                      &#226;&#710;&#8212; <br />                                                            &#226;&#710;&#8212;                      &#226;&#710;&#8212;                                                         &#226;&#710;&#8212; <br />                                                                                                             1000 <br />                                               # <br />                                250            &#226;&#710;&#8212;      &#226;&#710;&#8212;                                                                    &#226;&#710;&#8212;                                      # <br />                                                                                                              500                                                 &#226;&#710;&#8212;        &#226;&#710;&#8212; <br />                                                                                                                                                                               # <br />                                                                                                                                                                               &#226;&#710;&#8212; <br />                                  0                                                                                0 <br />                                       5            12              19           26                                        5             12             19             26 <br />                                                   Days infection                                                                 Days infection <br />  <br />                                      WT                            WT infected                                        WT                                WT infected <br />                                      5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217;                       5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; infected                                   5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217;                           5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; infected <br />  <br />                                                     (e)                                                                                     (f) <br />  <br /> Figure 3: Cytokine production spleen cells T. cruzi-infected mice. Spleen cells control, infected WT infected 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; <br /> mice (&#240;?&#8216;&#8250; = 10/group) cultured medium alone. Data independent experiments. Kruskal-Wallis test (&#226;&#710;&#8212; &#240;?&#8216;&#402; &lt; 0.01 versus <br /> uninfected group; # &#240;?&#8216;&#402; &lt; 0.05 versus infected WT mice). <br />  8                                                                                                                                                                                                                                    Mediators Inflammation <br />  <br />  <br />                                                                                         Gr-1+                                                                                                                        Gr-1+ CD11c+ <br />                                                            160                      #                                                                                                        50 <br />                                                                                                                                                                                                                             # <br />  <br />  <br />  <br />  <br />                                                                                                                                                                Number spleen cells &#195;&#8212;105 <br />                              Number spleen cells &#195;&#8212;105 <br />  <br />                                                                                                                                                                                              40 <br />                                                            120 <br />  <br />                                                                                                                                                                                              30 <br />                                                             80 <br />                                                                                                         #                                                                                    20          # <br />                                                                                                                    # <br />                                                             40 <br />                                                                                                                                                                                              10                                                         # <br />  <br />                                                              0                                                                                                                               0 <br />                                                                       5          12             19                 26                                                                                    5              12                 19           26 <br />                                                                            Days infection                                                                                                                     Days infection <br />                                                                               (a)                                                                                                                                     (b) <br />                                                                                            + <br />                                                            300                    CD11b                                                                                                 400                                 F4/80+         # <br />                            Number spleen cells &#195;&#8212;10 5 <br />  <br />  <br />  <br />  <br />                                                                                                                                                        Number spleen cells &#195;&#8212;10 5 <br />                                                                                                                                                                                         300                                 # <br />                                                            200 <br />  <br />                                                                                                                                                                                         200 <br />                                                                                                                    # <br />                                                                                                         # <br />                                                            100 <br />                                                                                     # <br />                                                                      #                                                                                                                  100 <br />                                                                                                                                                                                                           # <br />  <br />                                                             0                                                                                                                                 0 <br />                                                                      5           12             19                 26                                                                                     5              12             19              26 <br />                                                                            Days infection                                                                                                                    Days infection <br />                                                                  WT                             WT infected                                                                                           WT                             WT infected <br />                                                                  5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217;                        5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; infected                                                                                      5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217;                        5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; infected <br />                                                                               (c)                                                                                                                                     (d) <br />                                                                                                                        Number parasites recovered M&#240;?&#339;&#8482; <br />         Number parasites associated M&#240;?&#339;&#8482; <br />  <br />  <br />  <br />  <br />                                                  16                                                 #                                                                   200000 <br />  <br />  <br />                                                  12                                                                                                                     150000 <br />  <br />  <br />                                                      8                                                                                                                  100000 <br />  <br />  <br />                                                      4                                                                                                                           50000 <br />  <br />                                                                                                                                                                                                                                                 # <br />                                                      0                                                                                                                                            0 <br />                                                                      WT                           5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217;                                                                                                     WT                           5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; <br />                                                                             (e)                                                                                                                                       (f) <br />  <br /> Figure 4: Quantitative functional leukocyte responses T. cruzi infection. (a) Gr1+ cell (neutrophils); (b) Gr1+ CD11c+ cell (pDC cells); <br /> (c) CD11b+ cell (myeloid lineage cell marker, Mac-1); (d) F4/80+ cell (macrophages) numbers spleen. <br />  <br />  <br /> and stimulated anti-CD3&#240;?&#339;&#8364; presented partially restored                                                                                                          measured (Figure 3), IL-2. Spleen cells <br /> proliferative capacity.                                                                                                                                               collected infected WT mice day 12 stimulated <br />     Spleen cells collected infected mice days                                                                                                            anti-CD3&#240;?&#339;&#8364; produced significant amounts type 1 <br /> 12 26 inoculation, stimulated                                                                                                         cytokine (Th1) IFN-&#240;?&#8250;&#190;, type 2 cytokine (Th2) IL-10, as <br /> with anti-CD3&#240;?&#339;&#8364;. The supernatants tested pres-                                                                                                            low levels IL-2 (Figure 7(b)). In contrast, anti- <br /> ence IFN-&#240;?&#8250;&#190; IL-10, abundant cytokines                                                                                                           CD3&#240;?&#339;&#8364;-stimulated spleen cells collected infected 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; <br /> secreted spontaneously spleen cells infected mice                                                                                                             mice day 12 presented bias produce predominantly, <br />  Mediators Inflammation                                                                                                                                                                    9 <br />  <br />                                                                                                                                                       Anti-T. cruzi <br />                                                            +                                                             2800 <br />                                                    CD19 B-cells <br />                                   250                                                                                    2400 <br />  <br />  <br />  <br />  <br />                                                                                           Reciprocal serum dilution <br />                                                                                      # <br />                                                                                                                          2000 <br />     Number spleen cells &#195;&#8212;105 <br />  <br />  <br />  <br />  <br />                                   200 <br />                                                                          #                                                                                              # <br />                                                                                                                          1600 <br />                                   150 <br />                                                                                                                          1200                                                            # <br />                                             # <br />                                   100                                                                                     800 <br />                                                       #                                                                                           # <br />                                                                                                                           400 <br />                                   50 <br />                                                                                                                             0 <br />  <br />  <br />  <br />  <br />                                                                                                                                 IgG <br />  <br />  <br />                                                                                                                                        IgG1 <br />  <br />  <br />                                                                                                                                               IgG2a <br />  <br />  <br />  <br />  <br />                                                                                                                                                                       IgG <br />  <br />  <br />                                                                                                                                                                               IgG1 <br />  <br />  <br />                                                                                                                                                                                      IgG2a <br />                                     0 <br />                                             5           12               19          26 <br />                                                   Days infection                                                               Day 19                                 Day 26 <br />                                         WT                        WT infected                                                    WT <br />                                         5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217;                   5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; infected                                               5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; <br />                                                      (a)                                                                                              (b) <br />  <br /> Figure 5: (a) Splenic CD19+ B-cell counts control, infected WT infected 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice (&#240;?&#8216;&#8250; = 10/group). Data three <br /> independent experiments. Student&#226;&#8364;&#8482;s &#240;?&#8216;&#161;-test (# &#240;?&#8216;&#402; &lt; 0.01 versus infected WT mice). (b) T. cruzi-specific serum antibody titers infected WT <br /> and 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice (&#240;?&#8216;&#8250; = 10/group). Data independent experiments. # &#240;?&#8216;&#402; &lt; 0.001 versus infected WT mice. <br />  <br />  <br />  <br />  <br /> and greater quantities, Th1 cytokines, producing lower                                                   infected 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice infected WT mice. However, <br /> quantities Th2 cytokines greater quantities IL-2.                                                 differences infected 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice <br />      On day 26 inoculation, infected WT mouse spleen                                                  infected WT mice terms numbers CD8+ <br /> cells stimulated anti-CD3&#240;?&#339;&#8364; exhibited bias pro-                                                    effector/memory T cells. <br /> duce Th1 cytokine IFN-&#240;?&#8250;&#190; quite high amounts                                                          We questioned kinetic differences between <br /> (Figure 7(b)). However, infected 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mouse spleen cells                                                 infected 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice infected WT mice terms of <br /> receiving treatment presented alterations                                                increase CD4+ CD25+ T cell numbers (Figure 6(e)) <br /> cytokine production profile, sustained capacity produce                                                related involvement regulatory T cells this <br /> detectable levels IL-2, high (and predominant) levels                                                model. Figure 7(f) shows T. cruzi-infected mice exhib- <br /> of Th1 cytokines, low levels Th2 cytokines, day                                            ited increased numbers CD4+ CD25+ GITR+ regulatory T <br /> 12.                                                                                                         cells. However infected WT mice 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice exhibited <br />      Since anti-CD3&#240;?&#339;&#8364; promotes polyclonal T-cell stimula-                                                  similar numbers splenic CD4+ CD25+ GITR+ regulatory T <br /> tion, investigated IFN-&#240;?&#8250;&#190; IL-10 pro-                                                     cells. Unexpectedly, numbers CD4+ CD25+ GITR+ in <br /> duced primed T. cruzi-specific cells. We tested recall                                               spleen lower uninfected 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice in <br /> responses spleen cells collected day 12 inoculation                                             uninfected WT mice. <br /> and cultured soluble T. cruzi antigens. T. cruzi-specific <br /> cells infected WT mice cultured nominal antigens                                                  3.10. Levels LTC4 , Serum Nitrite Levels, Protein <br /> produced IFN-&#240;?&#8250;&#190; IL-10, T. cruzi-specific cells                                                   Extravasation Peritoneal Cavity Acute <br /> from infected 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice produced recall response,                                                      Phase T. cruzi Infection. The cys-LTs mediate detrimental <br /> characterized high levels IFN-&#240;?&#8250;&#190; lower levels IL-                                               vascular effects systemic infections sepsis [23]. <br /> 10, culture.                                                                                    Vasoactive mediators produced involved <br />      These results regarding recall response suggested                                              mortality animals acute phase T. <br /> presence functional parasite-specific effector/memory                                                    cruzi infection [35]. Thus, examined levels of <br /> T cells. Therefore, sought study populations                                                   vasoactive mediators NO metabolites, LTC4 , <br /> effector/memory T cells. As shown Figure 7, infected mice                                                measured protein leak (as marker vascular <br /> exhibited increased numbers splenic effector/memory T                                                    permeability) time point infected WT mice have <br /> cells CD4+ CD8+ subsets, including CD4+ CD45RBlow ,                                                  high mortality infected 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice not. As <br /> CD4+ CD44high CD62Llow , CD8+ CD45RBlow , CD8+ CD                                                       illustrated Figure 8, capacity produce LTC4 was <br /> 44high CD62Llow , day 26 inoculation. Inter-                                                       markedly upregulated peritoneal cells infected WT <br /> estingly, numbers effector/memory T cells                                                            mice day 22 inoculation, although, expected, those <br /> CD4+ CD45RBlow CD4+ CD44high CD62Llow higher                                                       infected 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice produced detectable levels of <br />  10                                                                                                                                                                                                               Mediators Inflammation <br />  <br />  <br />                                                                 CD4+ CD69+                                                                                                                             CD8+ CD69+ <br />                                              30                                                                                                                        12 <br />                Number spleen cells &#195;&#8212;105 <br />  <br />  <br />  <br />  <br />                                                                                                                                         Number spleen cells &#195;&#8212;105 <br />                                              20                                                                                                                        8 <br />  <br />                                                                                                                                                                                                                                 # <br />  <br />                                              10                                                                               #                                        4 <br />                                                                                                                                                                                                                     # <br />                                                                                                                                                                                                          # <br />  <br />  <br />                                              0                                                                                                                         0 <br />                                                   5       12                                             19                   26                                                        5             12             19        26 <br />                                                           Days infection                                                                                                                  Days infection <br />                                                                 (a)                                                                                                                                    (b) <br />                                                                       + <br />                                                                CD4 CD44                              +                                                                                              CD8+ CD44+ <br />                                       300                                                                                                                              125 <br />  <br />  <br />  <br />  <br />                                                                                                                                          Number spleen cells &#195;&#8212;105 <br />         Number spleen cells &#195;&#8212;105 <br />  <br />  <br />  <br />  <br />                                                                                                                                                                        100 <br />                                       200 <br />                                                                                                                                                                         75                                                      # <br />                                                                                                                               #                                                                                         # <br />                                                                                                               #                                                         50 <br />                                       100                         #                                                                                                                                          # <br />                                                       #                                                                                                                 25 <br />  <br />                                               0                                                                                                                             0 <br />                                                       5         12             19                                             26                                                            5          12             19        26 <br />                                                           Days infection                                                                                                                   Days infection <br />                                                                 (c)                                                                                                                                    (d) <br />                                                                                                                                                    +                            + <br />                                                                                                                                   CD4 CD25 <br />                                                                                                     30 <br />                                                                       Number spleen cells &#195;&#8212;105 <br />  <br />  <br />  <br />  <br />                                                                                                     20 <br />                                                                                                                                                                                                    # <br />  <br />  <br />                                                                                                     10                              #                                               # <br />                                                                                                                   # <br />  <br />  <br />  <br />                                                                                                     0 <br />                                                                                                                   5               12             19                                               26 <br />                                                                                                                             Days infection <br />  <br />                                                                                                               WT                                                       5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; <br />                                                                                                               WT infected                                              5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; infected <br />                                                                                                                                   (e) <br />  <br /> Figure 6: Splenic T-cell subpopulations control, infected WT infected 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice (&#240;?&#8216;&#8250; = 8/group). Data three <br /> independent experiments. Student&#226;&#8364;&#8482;s &#240;?&#8216;&#161;-test (# &#240;?&#8216;&#402; &lt; 0.01 versus infected WT mice). <br />  <br />  <br />  <br /> LTC4 . At time point, infected 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice presented                                                                                          degree protein leakage similar groups <br /> significantly lower serum nitrite levels did infected WT                                                                                       infected animals. Although 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice presented <br /> mice. In addition, peritoneal cavity protein extravasation                                                                                      tendency greater protein leakage did WT <br /> assays (Figure 8(c)) indicated days 14 19,                                                                                          mice, difference significant. However, day <br />  Mediators Inflammation                                                                                                                                                                                                                                                                                        11 <br />  <br />  <br />                                                                                                                                                                                                                                9000                              T cells cytokine profile <br />                                                                                                                                                                                                                                                                   # <br />  <br />  <br />  <br />  <br />                                                                                                                                                                                                      Cytokines (pg/mL) <br />                                                                                        T cell proliferation                                                                                                                                                                                              # <br />                               1.0                                                                                                                    5                                                                         6000 <br />  <br />  <br />  <br />  <br />                                                                                                                                                           Stimulation index (SI) <br />                               0.8                                                                                                                    4 <br />           MTT (570 nm) <br />  <br />  <br />  <br />  <br />                               0.6                                                                                                                    3                                                                         3000 <br />                                                                                                                                                                                                                                                                                                              # <br />                                                                                                                                      &#226;&#710;&#8212;# <br />                                                                                                                                                                                                                                                                        #                             # <br />                               0.4                                                                                                                    2                                                                                                       # <br />                                                                                                                                                                                                                                               0 <br />                                                                                          &#226;&#710;&#8212; <br />                               0.2                                                                                                                    1 <br />                                                                                                                                                                                                                                                   WTi +          5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217;            WTi +          5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; + <br />                                                                                                                                                                                                                                                   &#240;?&#8250;&#188;CD3                              &#240;?&#8250;&#188;CD3             &#240;?&#8250;&#188;CD3 <br />                                                                                                                                                                                                                                                                  + &#240;?&#8250;&#188;CD3 <br />                               0.0                                                                                                                                                                                                                    Day 12                                      Day 26 <br />                                                                                                                                                      0 <br />                                                                  WT + &#240;?&#8250;&#188;CD3 WT inf. +                   5-LO    &#226;&#710;&#8217;/&#226;&#710;&#8217; <br />                                                                                                              + 5-LO   inf. +         &#226;&#710;&#8217;/&#226;&#710;&#8217;                                                                                                            IL-2                                    IL-10 <br />                                                                             &#240;?&#8250;&#188;CD3                        &#240;?&#8250;&#188;CD3       &#240;?&#8250;&#188;CD3                                                                                                                             IFN-&#240;?&#8250;&#190; <br />                                                                                                  (a)                                                                                                                                                                        (b) <br />  <br />                                                                  3000                  T. cruzi Ag-induced cytokines <br />                                                                                                                                                      &#226;&#710;&#8212;# <br />                                                                                                                                                                                                                                                                        CD45RBlow <br />                                                                  2500 <br />                                                                                                                                      &#226;&#710;&#8212;#                                                                                                      12                        &#226;&#710;&#8212;# <br />  <br />                                                                                                                                                                                                              Number T cells spleen &#195;&#8212;106 <br />                                                                  2000 <br />                      Cytokines (pg/mL) <br />  <br />  <br />  <br />  <br />                                                                                                        &#226;&#710;&#8212; <br />                                                                  1500                                                #                                                                                                                        8               &#226;&#710;&#8212; <br />  <br />                                                                  1000                   &#226;&#710;&#8212;                  &#226;&#710;&#8212; <br />  <br />                                                                                                                                                                                                                                                                                                  &#226;&#710;&#8212;       &#226;&#710;&#8212; <br />                                                                   500                                                                                        &#226;&#710;&#8212;#                                                                               4 <br />                                                                                                                          # <br />                                                                       0 <br />                                                                                    (10 &#240;?&#339;&#8225;g) <br />                                                                            WTi + <br />                                                                           medium <br />  <br />  <br />  <br />  <br />                                                                                                    (50 &#240;?&#339;&#8225;g) <br />  <br />                                                                                                                  5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; + <br />                                                                                    WTi + <br />  <br />  <br />  <br />  <br />                                                                                                                                                  5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; + <br />                                                                                                    WTi + <br />  <br />  <br />  <br />  <br />                                                                                                                                    5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; + <br />                                                                                    Tc Ag <br />  <br />  <br />                                                                                                    Tc Ag <br />  <br />  <br />  <br />  <br />                                                                                                                                      (10 &#240;?&#339;&#8225;g) <br />  <br />  <br />                                                                                                                                                    (50 &#240;?&#339;&#8225;g) <br />                                                                                                                  medium <br />  <br />  <br />  <br />  <br />                                                                                                                                                     Tc Ag <br />                                                                                                                                       Tc Ag <br />  <br />  <br />  <br />  <br />                                                                                                                                                                                                                                               0 <br />                                                                                                                                                                                                                                                           CD4+                         CD8+ <br />  <br />                                                                               IFN-&#240;?&#8250;&#190;                                                                                                                                                                 WT                               WT infected <br />                                                                               IL-10                                                                                                                                                                 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217;                          5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; infected <br />  <br />                                                                                                    (c)                                                                                                                                                                     (d) <br />                                                                                                            low <br />                                                                  35                              CD62L <br />                                                                                                  &#226;&#710;&#8212;#                                                                                                                      4.5                              CD4+ CD25+ GITR+ <br />                               6 <br />  <br />  <br />  <br />  <br />                                                                                                                                         &#226;&#710;&#8212; <br />                                   Number T cells spleen &#195;&#8212;10 <br />  <br />  <br />  <br />  <br />                                                                  30 <br />                                                                                                                                                                                                                                                                         &#226;&#710;&#8212; <br />                                                                                                                                                                                    Number T cells spleen &#195;&#8212;106 <br />  <br />  <br />  <br />  <br />                                                                  25                         &#226;&#710;&#8212;                                                                                                                            3.6                                                                 &#226;&#710;&#8212; <br />                                                                                                                                                  &#226;&#710;&#8212; <br />                                                                  20 <br />                                                                                                                                                                                                                          2.7 <br />                                                                  15 <br />                                                                  10                                                                                                                                                      1.8 <br />  <br />                                                                   5                                                                                                                                                      0.9 <br />                                                                                                                                                                                                                                                                       &#226;&#710;&#8482; <br />                                                                   0 <br />                                                                                    +            high                           +            high <br />                                                                             CD4 CD44                                 CD8 CD44                                                                                            0.0 <br />  <br />                                                                            WT                                            WT infected                                                                                                               WT                              WT infected <br />                                                                            5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217;                                       5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; infected                                                                                                          5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217;                         5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; infected <br />  <br />                                                                                                   (e)                                                                                                                                                                 (f) <br />  <br /> Figure 7: Splenic T-cell properties, effector/memory T cells, regulatory T cells control, infected WT infected 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice (&#240;?&#8216;&#8250; = <br /> 8/group): (a) proliferation; (b) cytokine production profile anti-CD3 stimulation; (c) Th1/Th2 cytokine recall response soluble <br /> T. cruzi antigen. &#226;&#710;&#8212; &#240;?&#8216;&#402; &lt; 0.001 versus uninfected group; # &#240;?&#8216;&#402; &lt; 0.001 versus infected WT mice. (d) CD4+ CD45RBlow CD8+ CD45RBlow ; (e) <br /> CD4+ CD44high CD62Llow CD8+ CD44high CD62Llow ; (f) CD4+ CD25+ GITR+ . Stimulation index (SI) generated ratio between <br /> the OD (570 nm) obtained noninfected/infected cells. Data independent experiments. Student&#226;&#8364;&#8482;s &#240;?&#8216;&#161;-test (# &#240;?&#8216;&#402; &lt; 0.01 versus <br /> infected WT mice). <br />  12                                                                                                                                                          Mediators Inflammation <br />  <br />  <br />                                       120                                                                        900                                            &#226;&#710;&#8212; <br />                                                                             &#226;&#710;&#8212; <br />                  Serum nitrite (&#240;?&#339;&#8225;M) <br />  <br />  <br />  <br />  <br />                                                                                                  LTC 4 (pg/mL) <br />                                           80                                                                     600 <br />  <br />                                                                                            &#226;&#710;&#8212;# <br />  <br />  <br />                                           40                                                                     300 <br />  <br />  <br />  <br />                                                                                                                                                                       #        # <br />                                            0                                                                           0 <br />  <br />                                                  WT                     WT infected                                              WT                         WT infected <br />                                                  5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217;                5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; infected                                         5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217;                    5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; infected <br />  <br />                                                               (a)                                                                                 (b) <br />                                       6 <br />                                                                                     &#226;&#710;&#8212;                                  100 <br />  <br />                                       5                                                                                90 <br />                                                                                                                        80 <br />                                       4                                &#226;&#710;&#8212;                                               70 <br />                                                                                                         Survival (%) <br />      Evans blue (mg/mL) <br />  <br />  <br />  <br />  <br />                                                                                                                        60                                                      P &lt; 0.005 <br />                                       3               &#226;&#710;&#8212; <br />                                                                &#226;&#710;&#8212;                                                       50 <br />                                                                                                                        40 <br />                                       2                                                      # <br />                                                                                                                        30 <br />                                                                                                                        20 <br />                                       1 <br />                                                                                                                        10 <br />                                       0                                                                                    0 <br />                                                  14               19                    22                                   0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 <br />                                                            Days infection                                            Vehicle montelukast + + + + + + + + + + + <br />                                                                                                                                                Days infection <br />                                                WT                                                                                 Vehicle <br />                                                5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217;                                                                            Montelukast (10 mg/kg) <br />                                                               (c)                                                                                   (d) <br />  <br /> Figure 8: Levels vasoactive/vasomotor mediators relevance cys-LTs mice acutely infected T. cruzi (&#240;?&#8216;&#8250; = 10/group): (a) total <br /> serum nitrite (nitrite/nitrate) levels (b) LTC4 production peritoneal cells stimulation calcium ionophore. Data from <br /> one independent experiments. # &#240;?&#8216;&#402; &lt; 0.001 versus infected WT mice. (c) Protein extravasation peritoneal cavity (colorimetric <br /> assay extravascular dye leakage). Dotted line indicates mean Evans blue D.O. control mice. Data experiment <br /> representative separate experiments. # &#240;?&#8216;&#402; &lt; 0.05 versus infected WT mice. (d) Effect cys-LT receptor antagonist survival in <br /> T. cruzi-infected mice: (black squares) vehicle-treated infected WT mice (gray squares) infected WT mice treated montelukast <br /> (10 mg/kg) postinoculation day 14 postinoculation day 34 monitored 26 days. Data experiment representative <br /> of separate experiments. Wilcoxon signed-rank test # &#240;?&#8216;&#402; &lt; 0.005 versus vehicle-treated infected WT mice. <br />  <br />  <br />  <br /> 22, protein leakage peritoneal cavity considerably                                            mortality) achieved treatment montelukast <br /> greater infected WT mice infected 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217;                                             (Figure 8(d)). <br /> mice. <br />  <br /> 3.11. Treatment Infected Mice cys-LTs Receptor Antago-                                           4. Discussion <br /> nist Mortality. To determine cysLTs involved <br /> in mortality T. cruzi-infected mice, WT mice                                                 Leukotrienes, products 5-LO pathway arachidonic <br /> subjected infection T. cruzi treated cysLT                                          acid metabolism, potent immunomodulatory lipids that <br /> receptor antagonist montelukast day 14 day 34                                              increasingly recognized regulate innate adaptive <br /> inoculation. On day 40 inoculation, mortality                                                 immune responses parasitic infections [36]. Despite the <br /> among vehicle-treated control WT mice 82%,                                                     relevance LTs T. cruzi killing macrophages vitro <br /> moderately significant degree protection (reduction 48%                                            controlling blood parasite numbers vivo <br />  Mediators Inflammation                                                                                                        13 <br />  <br /> [26, 37, 38], oxidative balance 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; T. cruzi infected   induce IL-1&#240;?&#8250;&#189; production [45]; seen a <br /> mice related 5-LO-pathway independent [39].         unique inducer, presume that, 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice, IL- <br /> Different results NO cytokines productions            1&#240;?&#8250;&#189; IL-6 induced T. cruzi PAMPs (Pathogen <br /> observed acute phase T. cruzi Y strain infection     Associated Molecular Patterns), previously described [46]. <br /> of 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice related resistance [40]              In murine models fungal bacterial infection, <br /> or susceptibility [41]. The localized presence TCD8+         suggested pharmacological impairment LT <br /> TCD4+ heart demonstrated T. cruzi 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217;            biosynthesis hindered production Th1 cytokines <br /> infected mice [40], cell types and/or eicosanoid         IL-12 IFN-&#240;?&#8250;&#190; [20, 21]. However, model, 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; <br /> mediators investigated complete immune         T. cruzi infected mice exhibited increased capacity to <br /> response analysis. The novel finds study focus          produce IL-12 IFN-&#240;?&#8250;&#190;. A similar result obtained in <br /> the vivo role 5-LO metabolites cells related           infection models using 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice [22, 29, 30], and <br /> innate/adaptive immune responses, resistance, mortality        capacity essential achieving protective <br /> during acute phase T. cruzi murine infection. It         immunity pathogens mice [22, 47]. Previous <br /> important note analysis performed day sixteen        studies demonstrated quality quantity of <br /> after infection using infected mice survived     inflammatory mediators IL-12, IFN-&#240;?&#8250;&#190;, IL-10 <br /> up time point. Furthermore, results     released weeks infection critical to <br /> 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice infection, using T. cruzi Colombian strain, con-      driving generation parasite-specific effector T cells [48] <br /> tributing better understanding immune response         suggest early IL-12 IFN-&#240;?&#8250;&#190; production during <br /> and pathology Chagas&#226;&#8364;&#8482; disease.                              infection regulated LTs. It probable splenic <br />     Our data peritoneal cells infected WT           Gr-1+ CD11c+ plasmacytoid dendritic cells, Gr-1+ neutrophils, <br /> mice develop enhanced capacity produce LTB4 , LTC4 ,         F4/80+ macrophages sources IL-12 IFN-&#240;?&#8250;&#190;, <br /> and PGE2 compared cells obtained uninfected              numbers cells significantly <br /> mice, implicating LTs PGs host response T.           higher 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; infected mice WT infected mice. <br /> cruzi parasitic infection. Compared WT, 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice          These cell types increased T. <br /> developed significantly reduced parasitemia, lower tissue          cruzi infection models [10, 49], relevant <br /> parasitism, inflammatory cell infiltrates,        source IL-12 IFN-&#240;?&#8250;&#190; setting protozoal infection <br /> as significant improvement survival. Our curve             [50, 51]. Furthermore, IL-12-producing CD11c+ cells were <br /> parasitemia showed different profile compared           elevated 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; model M. tuberculosis <br /> previous publications [40, 41]. However, publications        infection [22]. <br /> are different them, to <br />                                                                         There evidence LTs contribute process of <br /> different trypomastigotes used infect exper- <br />                                                                    T-cell activation/migration different models [52, 53]. Our <br /> imental groups mice, work used cell culture- <br />                                                                    results demonstrated importance 5-LO products T- <br /> derived trypomastigotes [40] used mice-derived <br />                                                                    cell activation T. cruzi infection. Although reduction <br /> trypomastigotes [41]. Moreover, works used Y strain <br />                                                                    numbers activated splenic T cells achieved in <br /> of T. cruzi, used Colombian strain. <br />     These scenarios suggest LTs deficiency renders mice       infected 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice, T cells animals, <br /> more resistant T. cruzi infection conversely 5-        opposed WT mice, presented partially <br /> LO products confer susceptibility T. cruzi virulence. The       recovered capacity proliferate anti-CD3&#240;?&#339;&#8364; stimulation <br /> production proinflammatory cytokines IL-1&#240;?&#8250;&#189;, IL-6, IL-           produce IL-2 anti-CD3&#240;?&#339;&#8364; stimulation the <br /> 12, TNF-&#240;?&#8250;&#188;, IFN-&#240;?&#8250;&#190; presence parasite-specific         presence T. cruzi soluble antigens. We accordance <br /> T cells generating predominantly IFN-&#240;?&#8250;&#190; low levels           previous studies showing LTs inhibit T cell <br /> IL-10 associated increased efficiency 5-           proliferation IL-2 production [54] susceptibility <br />                                                                    T. cruzi infection associated elevated numbers <br /> LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice control infection blood and <br />                                                                    polyclonal activated T cells spleen [55] with <br /> tissue compartments. In fact, later phases infection, <br />                                                                    splenic T cell unresponsiveness mitogens inability <br /> parasitemia tissue parasitism significantly reduced <br />                                                                    secrete IL-2 [56]. Furthermore, resistance T. cruzi <br /> in 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice accordance previous studies      infection 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice, contrast susceptibility <br /> showing cytokines IL-1&#240;?&#8250;&#189;, IL-6, IL-12, TNF-&#240;?&#8250;&#188;,      WT mice, correlated elevated numbers splenic <br /> IFN-&#240;?&#8250;&#190; play relevant role host killing mechanisms against <br />                                                                    effector/memory T cells, including CD4+ CD45RBlow and <br /> T. cruzi [8]. <br />     Consistent data, evidence LTs induce    CD4+ CD44high CD62Llow , end acute phase <br /> TNF-&#240;?&#8250;&#188; [38] PGE2 [42] release. In models,           infection. Elevated numbers T cells expressing these <br /> been observed drug-induced genetic LTs deficiency          phenotypes associated IFN-&#240;?&#8250;&#190; production and <br /> increased PGE2 levels [43]. We observed 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice          resistance T. cruzi infection [11]. <br /> presented sustained potential produce PGE2 late             The correlation resistance infection and <br /> phase infection. In support findings LTB4           Th1 bias CD4+ T cells identified 5- <br /> induced IL-6, healthy patients subjected inhalation          LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice infected pathogens, including M. <br /> swine house dust treated 5-LO inhibitor showed            tuberculosis [22] T. gondii [57]. The bias IFN-&#240;?&#8250;&#190; <br /> elevated IL-6 serum levels [44]. In addition, LTB4           production T cells 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice observed <br />  14                                                                                                     Mediators Inflammation <br />  <br /> following infections typical Th2-inducing pathogens            mouse models [65, 66] suggest also <br /> such S. mansoni [29] S. venezuelensis [30] leading           relevant vivo. The alteration B cell activation observed in <br /> these animals resistant susceptible              T. cruzi 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; infected mice explain lower serum <br /> to infection, respectively. The CD4+ CD25+ T cells number           levels parasite-specific IgG IgG2a end the <br /> abnormality T. cruzi 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; infected mice led          acute phase infection. It previously described LT <br /> to investigate CD4+ CD25+ regulatory T cells.         deficiency altered specific-immunoglobulin class switching <br /> We WT 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; infected mice presented                specific pathogens vivo [29, 30]. Indeed, LTs may <br /> similar numbers splenic CD4+ CD25+ GITR+ regulatory T            affect parasite-specific antibody levels infection and <br /> cells. This does completely rule involvement         parasite-specific IgG IgG2a involved 5- <br /> CD4+ CD25+ regulatory T cells present model. In fact,        LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mouse resistance T. cruzi infection. This reinforces <br /> it recently demonstrated CD4+ CD25+ regulatory T           previous observation host resistance acute <br /> cells play limited role acute chronic phases       phase T. cruzi infection achieved absence of <br /> of T. cruzi infection [58].                                         B cells [67]. <br />      Phagocytes long known play important                Animal mortality acute phase T. cruzi <br /> role T. cruzi killing process [59]. It known    infection associated multiple factors, including <br /> IFN-&#240;?&#8250;&#190; major mediators conferring resistance           parasite strain virulence [68], anemia [69], increased levels of <br /> to T. cruzi [60]. Macrophage (F4/80+ ) numbers IFN-&#240;?&#8250;&#190;            TNF-&#240;?&#8250;&#188;, T-cell hyperactivity [70]. In fact, T. cruzi-infected <br /> were increased T. cruzi 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; infected mice.       mice shown extremely sensitive sepsis-like <br /> In vitro infection assays revealed activated PMs 5-       inducers die evidence shock syndrome [69]. <br /> LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice strongly associated efficient para-       We demonstrated T. cruzi-infected WT mice presented, <br /> site killing WT macrophages. These results corroborate         acute phase, upregulated production LTB4 and <br /> our vivo findings 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice efficient        LTC4 , high serum nitrite levels. In addition, the <br /> controlling parasitemia, contrasts previous vitro       analysis protein extravasation peritoneal cavity <br /> findings showing LTs foster intracellular parasite killing [26,     revealed infected WT mice exhibited stronger protein <br /> 38]. However, suggested 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice oxidative     leakage compared 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice. Previous studies <br /> stress occurs leukotriene-independent pathway,        showed LTs induce NO production macrophages and <br /> increase erythrocyte oxidative stress observed      endothelial cells [38], high levels NO production have <br /> animals [39]. Differences experimental design            associated increased mortality T. cruzi-infected <br /> our study previously published investigations warrant           mice [71]. LTs play critical role vascular events and <br /> discussion. Some differences results explained         mortality mice subjected cecal ligation puncture <br /> part macrophage activation and/or responsiveness          model sepsis [23]. We observed T. cruzi-infected <br /> LTs. We used classic activated macrophages (M1) vitro            WT mice treated montelukast presented significant <br /> [61], previous studies showing enhanced pathogen-           reduction mortality, providing evidence cys-LTs are <br /> killing properties LT-stimulated macrophages employed            involved vascular events associated mortality ani- <br /> resident peritoneal macrophages [26, 37], thioglycollate-           mals acute phase T. cruzi infection. It notable <br /> elicited macrophages [28, 38], alveolar macrophages [18].        montelukast treatment effective increasing <br /> The functional differences different types           survival contrast observed T. cruzi-infected 5- <br /> macrophages remarkable consistently               LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice. The deaths montelukast-treated animals <br /> described [62, 63]. The increased capacity macrophages           attributable presence 5-LO products, <br />                                                                     LTB4 , indirect effect inducing vasoactive <br /> from 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice kill intracellular pathogens pre- <br />                                                                     mediators NO [72] thromboxane [73]. However, <br /> viously described M. tuberculosis [22]. These findings <br />                                                                     unlike WT, 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; infected mice sustain production of <br /> underscore relevance IFN-&#240;?&#8250;&#190; killing activity of <br />                                                                     TNF-&#240;?&#8250;&#188; IL-6. This finding surprising, these <br /> macrophages 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice resistance T. cruzi infection,       cytokines shown vasoactive properties [35]. <br /> although data shed light LXA4 involved <br />                                                                          One reasonable mechanism explain WT mice mor- <br /> in parasite resistance mice, described for <br /> M. tuberculosis infection [22].                                     tality acute phase T. cruzi infection involves <br />      Analysis B cells indicated T. cruzi 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; infected   capacity produce LTs, lead extreme <br /> mice developed smaller increases numbers splenic          bias spleen cells T-cells secrete high levels of <br /> CD19+ B cells weeks did WT mice,          Th1 cytokines, IFN-&#240;?&#8250;&#190;, low levels IL- <br /> but followed increased numbers splenic CD19+         10. In addition, downregulated production PGE2 might <br /> B cells following weeks. The elevated numbers CD19+       relevant, PGE2 shown induce IL-10 <br /> B cells 5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; mice later phase infection       production [74], inhibit production IFN-&#240;?&#8250;&#190; T. <br /> might indicate accumulation undifferentiated B cells          cruzi infection, promote increased production NO <br /> in splenic compartment. This hypothesis supported         [75]. The advantage survival T. cruzi-5-LO&#226;&#710;&#8217;/&#226;&#710;&#8217; infected <br /> previous studies showing antibody-secreting B cells lose       mice represents complex contribution various effects on <br /> their CD19 marker [64]. Previous vitro findings showed           host defense, including capacity efficiently control the <br /> that LTs important activating B cells human           parasites produce detectable levels IL-10, increase <br />  Mediators Inflammation                                                                                                                         15 <br />  <br /> in production PGE2 , lesser amounts NO,                    infection involves minimal modulation host cell transcrip- <br /> their inability produce cys-LTs.                                             tion,&#226;&#8364;? The Journal Biological Chemistry, vol. 277, no. 1, pp. 639&#226;&#8364;&#8220; <br />                                                                                 644, 2002. <br />  <br /> 5. Conclusions                                                              [8] L. E. Fichera, M. C. Albareda, S. A. Laucella, M. Postan, <br />                                                                                 &#226;&#8364;&#339;Intracellular growth trypanosoma cruzi cardiac myocytes <br /> Our findings demonstrated 5-LO deficiency altered                          inhibited cytokine-induced nitric oxide release,&#226;&#8364;? Infection <br /> eicosanoids cytokines production T. cruzi infec-                     Immunity, vol. 72, no. 1, pp. 359&#226;&#8364;&#8220;363, 2004. <br /> tion favored generation/maintenance protective                   [9] F. S. Machado, G. A. Martins, J. C. S. Aliberti, F. L. A. C. <br /> immune responses. Also, provided evidence 5-LO-                       Mestriner, F. Q. Cunha, J. S. Silva, &#226;&#8364;&#339;Trypanosoma cruzi- <br /> derived lipid mediators negative effect host survival                 infected cardiomyocytes produce chemokines cytokines <br />                                                                                 trigger potent nitric oxide-dependent trypanocidal activ- <br /> during acute phase infection. <br />                                                                                 ity,&#226;&#8364;? Circulation, vol. 102, no. 24, pp. 3003&#226;&#8364;&#8220;3008, 2000. <br />                                                                            [10] A. C. Monteiro, V. Schmitz, E. Svensjo et al., &#226;&#8364;&#339;Cooperative <br /> Conflict Interests                                                           activation TLR2 bradykinin B2 receptor required for <br />                                                                                 induction type 1 immunity mouse model subcutaneous <br /> The authors declare conflict interests                      infection Trypanosoma cruzi,&#226;&#8364;? The Journal Immunology, <br /> regarding publication paper.                                        vol. 177, no. 9, pp. 6325&#226;&#8364;&#8220;6335, 2006. <br />                                                                            [11] A. Nomizo, F. Cardillo, E. Post&#194;&#180;ol, L. P. Carvalho, and <br /> Authors&#226;&#8364;&#8482; Contribution                                                           J. Mengel, &#226;&#8364;&#339;V&#240;?&#8250;&#190;1 &#240;?&#8250;&#190;&#240;?&#8250;&#191; T cells regulate type-1/type-2 immune <br />                                                                                 responses participate resistance infection and <br /> Adriana M. C. Canavaci Carlos A. Sorgi contributed                          development heart inflammation Trypanosoma cruzi- <br /> equally work.                                                           infected BALB/c mice,&#226;&#8364;? Microbes Infection, vol. 8, no. 3, pp. <br />                                                                                 880&#226;&#8364;&#8220;888, 2006. <br />                                                                            [12] R. L. Tarleton, B. H. Koller, A. Latour, M. Postan, &#226;&#8364;&#339;Suscepti- <br /> Acknowledgments                                                                 bility &#240;?&#8250;&#189;2-microglobulin-deficient mice Trypanosoma cruzi <br /> This work supported Fundac&#194;&#184;a&#203;&#339; o Amparo                          infection,&#226;&#8364;? Nature, vol. 356, no. 6367, pp. 338&#226;&#8364;&#8220;340, 1992. <br /> Pesquisa Estado S&#203;&#339;ao Paulo (FAPESP, Foundation                   [13] D. F. Hoft, A. R. Schnapp, C. S. Eickhoff, S. T. Rood- <br /> the Support Research State S&#203;&#339;ao Paulo). Adriana                    man, &#226;&#8364;&#339;Involvement CD4+ Th1 cells systemic immunity <br /> M. C. Canavaci recipient fellowship                        protective primary secondary challenges with <br /> Brazilian Conselho Nacional Desenvolvimento Cient&#194;&#180;&#196;&#177;fico                      Trypanosoma cruzi,&#226;&#8364;? Infection Immunity, vol. 68, no. 1, pp. <br />                                                                                 197&#226;&#8364;&#8220;204, 2000. <br /> e Tecnol&#194;&#180;ogico (CNPq, National Council Scientific and <br /> Technological Development).                                                [14] M. Peters-Golden, C. Canetti, P. Mancuso, M. J. Coffey, <br />                                                                                 &#226;&#8364;&#339;Leukotrienes: underappreciated mediators innate immune <br />                                                                                 responses,&#226;&#8364;? The Journal Immunology, vol. 174, no. 2, pp. 589&#226;&#8364;&#8220; <br /> References                                                                      594, 2005. <br /> [1] K. Senior, &#226;&#8364;&#339;Chagas disease: moving global elimina-             [15] M. Peters-Golden T. G. Brock, &#226;&#8364;&#339;5-Lipoxygenase FLAP,&#226;&#8364;? <br />     tion.,&#226;&#8364;? The Lancet infectious diseases, vol. 7, no. 9, p. 572, 2007.        Prostaglandins Leukotrienes Essential Fatty Acids, vol. 69, <br />                                                                                 no. 2-3, pp. 99&#226;&#8364;&#8220;109, 2003. <br /> [2] L. O. Andrade N. W. Andrews, &#226;&#8364;&#339;The Trypanosoma <br />     cruzi-host-cell interplay: Location, invasion, retention,&#226;&#8364;? Nature      [16] C. N. Serhan, M. Hamberg, B. Samuelsson, &#226;&#8364;&#339;Lipoxins: <br />     Reviews Microbiology, vol. 3, no. 10, pp. 819&#226;&#8364;&#8220;823, 2005.                    novel series biologically active compounds formed from <br />                                                                                 arachidonic acid human leukocytes,&#226;&#8364;? Proceedings the <br /> [3] Z. Brener R. T. Gazzinelli, &#226;&#8364;&#339;Immunological control of <br />                                                                                 National Academy Sciences United States America, <br />     Trypanosoma cruzi infection pathogenesis Chagas&#226;&#8364;&#8482; <br />                                                                                 vol. 81, no. 17, pp. 5335&#226;&#8364;&#8220;5339, 1984. <br />     disease,&#226;&#8364;? International Archives Allergy Immunology, vol. <br />     114, no. 2, pp. 103&#226;&#8364;&#8220;110, 1997.                                         [17] T. Demitsu, H. Katayama, T. Saito-Taki, H. Yaoita, M. <br /> [4] R. T. Gazzinelli, I. P. Oswald, S. Hieny, S. L. James,                  Nakano, &#226;&#8364;&#339;Phagocytosis bactericidal action mouse peri- <br />     A. Sher, &#226;&#8364;&#339;The microbicidal activity interferon-&#240;?&#8250;&#190;-treated                 toneal macrophages treated leukotriene B4,&#226;&#8364;? International <br />     macrophages Trypanosoma cruzi involves L-                        Journal Immunopharmacology, vol. 11, no. 7, pp. 801&#226;&#8364;&#8220;808, 1989. <br />     arginine-dependent, nitrogen oxide-mediated mechanism                  [18] M. B. Bailie, T. J. Standiford, L. L. Laichalk, M. J. Coffey, R. <br />     inhibitable interleukin-10 transforming growth factor-               Strieter, M. Peters-Golden, &#226;&#8364;&#339;Leukotriene-deficient mice <br />     &#240;?&#8250;&#189;,&#226;&#8364;? European Journal Immunology, vol. 22, no. 10, pp.                    manifest enhanced lethality Klebsiella pneumonia in <br />     2501&#226;&#8364;&#8220;2506, 1992.                                                            association decreased alveolar macrophage phagocytic and <br /> [5] C. A. Santos-Buch, &#226;&#8364;&#339;American trypanosomiasis: chagas&#226;&#8364;&#8482; dis-                  bactericidal activities,&#226;&#8364;? Journal Immunology, vol. 157, no. 12, <br />     ease,&#226;&#8364;? International Review Experimental Pathology, vol. 19,             pp. 5221&#226;&#8364;&#8220;5224, 1996. <br />     pp. 63&#226;&#8364;&#8220;100, 1979.                                                      [19] N. Chen, A. Restivo, C. S. Reiss, &#226;&#8364;&#339;Leukotrienes play <br /> [6] S. E. B. Graefe, T. Streichert, B. S. Budde et al., &#226;&#8364;&#339;Genes             protective roles early experimental VSV encephalitis,&#226;&#8364;? <br />     Chagas susceptibility loci differentially expressed             Journal Neuroimmunology, vol. 120, no. 1-2, pp. 94&#226;&#8364;&#8220;102, 2001. <br />     T. cruzi-resistant mice candidates accounting impaired         [20] A. I. Medeiros, A. S&#194;&#180;a-Nunes, E. G. Soares, C. M. Peres, C. L. <br />     immunity,&#226;&#8364;? PLoS ONE, vol. 1, no. 1, article e57, 2006.                      Silva, L. H. Faccioli, &#226;&#8364;&#339;Blockade endogenous leukotrienes <br /> [7] S. V. Avalos, I. J. Blader, M. Fisher, J. C. Boothroyd, B.           exacerbates pulmonary histoplasmosis,&#226;&#8364;? Infection Immu- <br />     A. Burleigh, &#226;&#8364;&#339;Immediate/early response Trypanosoma cruzi                 nity, vol. 72, no. 3, pp. 1637&#226;&#8364;&#8220;1644, 2004. <br />  16                                                                                                                   Mediators Inflammation <br />  <br /> [21] C. M. Peres, L. Paula, A. I. Medeiros et al., &#226;&#8364;&#339;Inhibition        [35] C. H&#194;&#168;olscher, M. Mohrs, W. J. Dai et al., &#226;&#8364;&#339;Tumor necrosis <br />       leukotriene biosynthesis abrogates host control Mycobac-             factor &#240;?&#8250;&#188;-mediated toxic shock Trypanosoma cruzi-infected <br />       terium tuberculosis,&#226;&#8364;? Microbes Infection, vol. 9, no. 4, pp.            interleukin 10-deficient mice,&#226;&#8364;? Infection Immunity, vol. 68, <br />       483&#226;&#8364;&#8220;489, 2007.                                                              no. 7, pp. 4075&#226;&#8364;&#8220;4083, 2000. <br /> [22] A. Bafica, C. A. Scanga, C. Serhan et al., &#226;&#8364;&#339;Host control            [36] A. P. Rogerio F. F. Anibal, &#226;&#8364;&#339;Role leukotrienes on <br />       Mycobacterium tuberculosis regulated 5-lipoxygenase-                  protozoan helminth infections,&#226;&#8364;? Mediators Inflammation, <br />       dependent lipoxin production,&#226;&#8364;? The Journal Clinical Investi-             vol. 2012, Article ID 595694, 13 pages, 2012. <br />       gation, vol. 115, no. 6, pp. 1601&#226;&#8364;&#8220;1606, 2005.                         [37] J. J. Wirth F. Kierszenbaum, &#226;&#8364;&#339;Effects leukotriene C4 <br /> [23] C. F. Benjamin, C. Canetti, F. Q. Cunha, S. L. Kunkel,                       macrophage association intracellular fate Try- <br />       M. Peters-Golden, &#226;&#8364;&#339;Opposing hierarchical roles                   panosoma cruzi,&#226;&#8364;? Molecular Biochemical Parasitology, vol. <br />       leukotrienes local innate immune versus vascular responses               15, no. 1, pp. 1&#226;&#8364;&#8220;10, 1985. <br />       model sepsis,&#226;&#8364;? Journal Immunology, vol. 174, no. 3, pp.    [38] A. Talvani, F. S. Machado, G. C. Santana et al., &#226;&#8364;&#339;Leukotriene B4 <br />       1616&#226;&#8364;&#8220;1620, 2005.                                                            induces nitric oxide synthesis Trypanosoma cruzi-infected <br /> [24] H. D&#226;&#8364;&#8482;Avila, C. G. Freire-de-Lima, N. R. Roque et al., &#226;&#8364;&#339;Host                  murine macrophages mediates resistance infection,&#226;&#8364;? <br />       cell lipid bodies triggered Trypanosoma cruzi infection              Infection Immunity, vol. 70, no. 8, pp. 4247&#226;&#8364;&#8220;4253, 2002. <br />       enhanced uptake apoptotic cells associated         [39] C. L. Borges, R. Cecchini, V. L. H. Tatakihara et al., &#226;&#8364;&#339;5- <br />       prostaglandin E2 generation increased parasite growth,&#226;&#8364;?                 Lipoxygenase plays role control parasite burden <br />       Journal Infectious Diseases, vol. 204, no. 6, pp. 951&#226;&#8364;&#8220;961, 2011.         contributes oxidative damage erythrocytes murine <br /> [25] L. Xiao, P. S. Patterson, C. Yang, A. A. Lal, &#226;&#8364;&#339;Role                   Chagas&#226;&#8364;&#8482; disease,&#226;&#8364;? Immunology Letters, vol. 123, no. 1, pp. 38&#226;&#8364;&#8220;45, <br />       eicosanoids pathogenesis murine cerebral malaria,&#226;&#8364;?                2009. <br />       American Journal Tropical Medicine Hygiene, vol. 60, no.       [40] W. R. Pavanelli, F. R. S. Gutierrez, F. S. Mariano et al., &#226;&#8364;&#339;5- <br />       4, pp. 668&#226;&#8364;&#8220;673, 1999.                                                       Lipoxygenase key determinant acute myocardial inflam- <br /> [26] J. J. Wirth F. Kierszenbaum, &#226;&#8364;&#339;Stimulatory effects                     mation mortality Trypanosoma cruzi infection,&#226;&#8364;? <br />       leukotriene B4 macrophage association intracellu-               Microbes Infection, vol. 12, no. 8-9, pp. 587&#226;&#8364;&#8220;597, 2010. <br />       lar destruction Trypanosoma cruzi,&#226;&#8364;? Journal Immunology,          [41] C. Panis, T. L. Mazzuco, C. Z. F. Costa et al., &#226;&#8364;&#339;Trypanosoma <br />       vol. 134, no. 3, pp. 1989&#226;&#8364;&#8220;1993, 1985.                                       cruzi: effect absence 5-lipoxygenase (5-LO)-derived <br /> [27] J. J. Wirth F. Kierszenbaum, &#226;&#8364;&#339;Effects leukotriene C4                  leukotrienes levels cytokines, nitric oxide iNOS <br />       macrophage association intracellular fate Try-               expression cardiac tissue acute phase infection in <br />       panosoma cruzi,&#226;&#8364;? Molecular Biochemical Parasitology, vol.               mice,&#226;&#8364;? Experimental Parasitology, vol. 127, no. 1, pp. 58&#226;&#8364;&#8220;65, 2011. <br />       15, no. 1, pp. 1&#226;&#8364;&#8220;10, 1985.                                            [42] A. Rossi, A. M. Acquaviva, F. Iuliano, R. di Paola, S. Cuzzocrea, <br /> [28] C. H. Serezani, J. H. Perrela, M. Russo, M. Peters-Golden, S.            L. Sautebin, &#226;&#8364;&#339;Up-regulation prostaglandin biosynthesis <br />       Jancar, &#226;&#8364;&#339;Leukotrienes essential control Leishmania           leukotriene C4 elicited mice peritoneal macrophages <br />       amazonensis infection contribute strain variation                 activated lipopolysaccharide/ interferon-&#240;?&#8250;&#190;,&#226;&#8364;? Journal of <br />       susceptibility,&#226;&#8364;? Journal Immunology, vol. 177, no. 5, pp. 3201&#226;&#8364;&#8220;          Leukocyte Biology, vol. 78, no. 4, pp. 985&#226;&#8364;&#8220;991, 2005. <br />       3208, 2006.                                                           [43] R. S. Byrum, J. L. Goulet, R. J. Griffiths, B. H. Koller, &#226;&#8364;&#339;Role of <br /> [29] W. E. Secor, M. R. Powell, J. Morgan, T. A. Wynn, C. D.                  5-lipoxygenase-activating protein (FLAP) murine acute <br />       Funk, &#226;&#8364;&#339;Mice deficient 5-lipoxygenase, leukocyte-                inflammatory responses,&#226;&#8364;? Journal Experimental Medicine, vol. <br />       type 12- lipoxygenase, display altered immune responses              185, no. 6, pp. 1065&#226;&#8364;&#8220;1075, 1997. <br />       infection Schistosoma mansoni,&#226;&#8364;? Prostaglandins Other         [44] B. M. Larsson, M. Kumlin, B. M. Sundblad, K. Larsson, S. E. <br />       Lipid Mediators, vol. 56, no. 5-6, pp. 291&#226;&#8364;&#8220;304, 1998.                       Dahl&#194;&#180;en, L. Palmberg, &#226;&#8364;&#339;Effects 5-lipoxygenase inhibitor <br /> [30] E. R. Machado, M. T. Ueta, E. V. Lourenc&#194;&#184;o et al., &#226;&#8364;&#339;Leukotrienes             zileuton airway responses inhaled swine house dust in <br />       play role control parasite burden murine strongy-            healthy subjects,&#226;&#8364;? Respiratory Medicine, vol. 100, no. 2, pp. 226&#226;&#8364;&#8220; <br />       loidiasis,&#226;&#8364;? The Journal Immunology, vol. 175, no. 6, pp. 3892&#226;&#8364;&#8220;           237, 2006. <br />       3899, 2005.                                                           [45] Y. Kageyama, Y. Koide, S. Miyamoto, T. O. Yoshida, T. <br />  [31] L. Xiao, P. S. Patterson, C. Yang, A. A. Lal, &#226;&#8364;&#339;Role                  Inoue, &#226;&#8364;&#339;Leukotrien B4-induced interleukin-1&#240;?&#8250;&#189; synovial cells <br />       eicosanoids pathogenesis murine cerebral malaria,&#226;&#8364;? The            patients rheumatoid arthritis,&#226;&#8364;? Scandinavian Journal <br />       American Journal Tropical Medicine Hygiene, vol. 60, no.             Rheumatology, vol. 23, no. 3, pp. 148&#226;&#8364;&#8220;150, 1994. <br />       4, pp. 668&#226;&#8364;&#8220;673, 1999.                                                 [46] A. Talvani, C. S. Ribeiro, J. C. S. Aliberti et al., &#226;&#8364;&#339;Kinetics of <br /> [32] F. Cardillo, F. Q. Cunha, W. M. S. C. Tamashiro, M. Russo,                   cytokine gene expression experimental chagasic cardiomy- <br />       S. B. Garcia, J. Mengel, &#226;&#8364;&#339;NK 1.1+ Cells T-cell acti-                opathy: tissue parasitism endogenous IFN-&#240;?&#8250;&#190; important <br />       vation euthymic thymectomized C57B1/6 mice                    determinants chemokine mRNA expression infection <br />       acute Trypanosoma cruzi infection,&#226;&#8364;? Scandinavian Journal                 Trypanosoma cruzi,&#226;&#8364;? Microbes Infection, vol. 2, no. 8, <br />       Immunology, vol. 55, no. 1, pp. 96&#226;&#8364;&#8220;104, 2002.                               pp. 851&#226;&#8364;&#8220;866, 2000. <br /> [33] I. A. Abrahamsohn, A. P. G. da Silva, R. L. Coffman, &#226;&#8364;&#339;Effects      [47] J. Aliberti, S. Hieny, C. Reis Sousa, C. N. Serhan, A. <br />       interleukin-4 deprivation treatment resistance                 Sher, &#226;&#8364;&#339;Lipoxin-mediated inhibition IL-12 production DCs: <br />       Trypanosoma cruzi,&#226;&#8364;? Infection Immunity, vol. 68, no. 4, pp.             mechanism regulation microbial immunity,&#226;&#8364;? Nature <br />       1975&#226;&#8364;&#8220;1979, 2000.                                                            Immunology, vol. 3, no. 1, pp. 76&#226;&#8364;&#8220;82, 2002. <br /> [34] G. N. R. Vespa, F. Q. Cunha, J. S. Silva, &#226;&#8364;&#339;Nitric oxide         [48] A. P. G. da Silva I. Almeida Abrahamsohn, <br />       involved control Trypanosoma cruzi-induced parasitemia                &#226;&#8364;&#339;Interleukin-12 stimulation lymphoproliferative responses <br />       directly kills parasite vitro,&#226;&#8364;? Infection Immunity,          Trypanosoma cruzi infection,&#226;&#8364;? Immunology, vol. 104, no. 3, <br />       vol. 62, no. 11, pp. 5177&#226;&#8364;&#8220;5182, 1994.                                       pp. 349&#226;&#8364;&#8220;354, 2001. <br />  Mediators Inflammation                                                                                                                         17 <br />  <br /> [49] O. Go&#203;&#339;no, P. Alcaide, M. Fresno, &#226;&#8364;&#339;Immunosuppression                [65] K. A. Yamaoka, H. E. Claesson, A. Rosen, &#226;&#8364;&#339;Leukotriene B4 <br />       acute Trypanosoma cruzi infection: involvement Ly6G               enhances activation, proliferation, differentiation human <br />       (Gr1+ )CD11b+ immature myeloid suppressor cells,&#226;&#8364;? Interna-                  B lymphocytes,&#226;&#8364;? Journal Immunology, vol. 143, no. 6, pp. 1996&#226;&#8364;&#8220; <br />       tional Immunology, vol. 14, no. 10, pp. 1125&#226;&#8364;&#8220;1134, 2002.                    2000, 1989. <br /> [50] C. H. Liu, Y. T. Fan, A. Dias et al., &#226;&#8364;&#339;Cutting edge: dendritic cells   [66] C. Phillips, &#226;&#8364;&#339;Induction leukotriene production antigen <br />       essential vivo IL-12 production development               challenge enhances antibody affinity genetically selected <br />       resistance Toxoplasma gondii infection mice,&#226;&#8364;? Journal            mice,&#226;&#8364;? Cellular Immunology, vol. 136, no. 1, pp. 173&#226;&#8364;&#8220;184, 1991. <br />       Immunology, vol. 177, no. 1, pp. 31&#226;&#8364;&#8220;35, 2006.                      [67] D. E. Burgess W. L. Hanson, &#226;&#8364;&#339;Trypanosoma cruzi: T-cell <br />  [51] D. G. Mordue L. D. Sibley, &#226;&#8364;&#339;A novel population Gr-1+ -               dependence primary immune response effects <br />       activated macrophages induced acute toxoplasmosis,&#226;&#8364;?                  depletion T cells Ig-bearing cells immunological <br />       Journal Leukocyte Biology, vol. 74, no. 6, pp. 1015&#226;&#8364;&#8220;1025, 2003.          memory,&#226;&#8364;? Cellular Immunology, vol. 52, no. 1, pp. 176&#226;&#8364;&#8220;186, 1980. <br /> [52] I. Prinz, C. Gregoire, H. Mollenkopf et al., &#226;&#8364;&#339;The type 1 cysteinyl     [68] V. Andrade, M. Barral-Netto, S. G. Andrade, &#226;&#8364;&#339;Patterns of <br />       leukotriene receptor triggers calcium influx chemotaxis              resistance inbred mice Trypanosoma cruzi determined <br />       mouse &#240;?&#8250;&#188;&#240;?&#8250;&#189;- &#240;?&#8250;&#190;&#240;?&#8250;&#191; effector T cells,&#226;&#8364;? The Journal Immunology,              parasite strain,&#226;&#8364;? Brazilian Journal Medical Biological <br />       vol. 175, no. 2, pp. 713&#226;&#8364;&#8220;719, 2005.                                         Research, vol. 18, no. 4, pp. 499&#226;&#8364;&#8220;506, 1985. <br /> [53] A. M. Tager, S. K. Bromley, B. D. Medoff et al., &#226;&#8364;&#339;Leukotriene B4       [69] M. C. G. Marcondes, P. Borelli, N. Yoshida, M. Russo, <br />       receptor BLT1 mediates early effector T cell recruitment,&#226;&#8364;? Nature           &#226;&#8364;&#339;Acute Trypanosoma cruzi infection associated anemia, <br />       Immunology, vol. 4, no. 10, pp. 982&#226;&#8364;&#8220;990, 2003.                              thrombocytopenia, leukopenia, bone marrow hypoplasia: <br /> [54] J. S. Goodwin, &#226;&#8364;&#339;Regulation T cell activation leukotriene               reversal nifurtimox treatment,&#226;&#8364;? Microbes Infection, vol. <br />       B4,&#226;&#8364;? Immunologic Research, vol. 5, no. 3, pp. 233&#226;&#8364;&#8220;248, 1986.                2, no. 4, pp. 347&#226;&#8364;&#8220;352, 2000. <br /> [55] N. Nogueira, J. Ellis, S. Chaplan, Z. Cohn, &#226;&#8364;&#339;Trypanosoma           [70] S. Hamano, K. Himeno, Y. Miyazaki et al., &#226;&#8364;&#339;WSX-1 required <br />       cruzi: In vivo vitro correlation T-cell activation           resistance Trypanosoma cruzi infection regulation of <br />       susceptibility inbred strains mice,&#226;&#8364;? Experimental                 proinflammatory cytokine production,&#226;&#8364;? Immunity, vol. 19, no. 5, <br />       Parasitology, vol. 51, no. 3, pp. 325&#226;&#8364;&#8220;334, 1981.                            pp. 657&#226;&#8364;&#8220;667, 2003. <br /> [56] A. Harel-Bellan, M. Joskowicz, D. Fradelizi, H. Eisen,              [71] F. Cardillo, A. Nomizo, E. Post&#194;&#180;ol, J. Mengel, &#226;&#8364;&#339;NK1.1 cells are <br />       &#226;&#8364;&#339;Modification T-cell proliferation interleukin 2 produc-             required control T cell hyperactivity Trypanosoma <br />       tion mice infected Trypanosoma cruzi,&#226;&#8364;? Proceedings               cruzi infection,&#226;&#8364;? Medical Science Monitor, vol. 10, no. 8, pp. <br />       National Academy Sciences United States America,           BR259&#226;&#8364;&#8220;BR267, 2004. <br />       vol. 80, no. 11, pp. 3466&#226;&#8364;&#8220;3469, 1983.                                 [72] H. Arndt, J. B. Russell, I. Kurose, P. Kubes, D. N. Granger, <br /> [57] J. Aliberti, C. Serhan, A. Sher, &#226;&#8364;&#339;Parasite-induced lipoxin               &#226;&#8364;&#339;Mediators leukocyte adhesion rat mesenteric venules <br />       A4 endogenous regulator IL-12 production                       elicited inhibition nitric oxide synthesis,&#226;&#8364;? Gastroenterol- <br />       immunopathology Toxoplasma gondii infection,&#226;&#8364;? Journal                 ogy, vol. 105, no. 3, pp. 675&#226;&#8364;&#8220;680, 1993. <br />       Experimental Medicine, vol. 196, no. 9, pp. 1253&#226;&#8364;&#8220;1262, 2002.          [73] K. Sakata, S.-E. Dahl&#194;&#180;en, M. B&#194;&#168;ack, &#226;&#8364;&#339;The contractile action <br /> [58] J. Kotner R. Tarleton, &#226;&#8364;&#339;Endogenous CD4+ CD25+ regula-                    leukotriene B4 guinea-pig lung involves vascular <br />       tory T cells limited role control Trypanosoma              component,&#226;&#8364;? British Journal Pharmacology, vol. 141, no. 3, pp. <br />       cruzi infection mice,&#226;&#8364;? Infection Immunity, vol. 75, no. 2,           449&#226;&#8364;&#8220;456, 2004. <br />       pp. 861&#226;&#8364;&#8220;869, 2007.                                                    [74] G. Strassmann, V. Patil-Koota, F. Finkelman, M. Fong, T. <br /> [59] D. M. Williams, S. Sawyer, J. S. Remington, &#226;&#8364;&#339;Role                     Kambayashi, &#226;&#8364;&#339;Evidence involvement interleukin 10 in <br />       activated macrophages resistance mice infection               differential deactivation murine peritoneal macrophages <br />       Trypanosoma cruzi,&#226;&#8364;? Journal Infectious Diseases, vol. 134, no.           prostaglandin E2,&#226;&#8364;? Journal Experimental Medicine, vol. 180, <br />       6, pp. 610&#226;&#8364;&#8220;614, 1976.                                                       no. 6, pp. 2365&#226;&#8364;&#8220;2370, 1994. <br /> [60] F. Torrico, H. Heremans, M. T. Rivera, E. Van Marck, A. Billiau,       [75] M. A. Michelin, J. S. Silva, F. Q. C. Cunha, &#226;&#8364;&#339;Inducible <br />       Y. Carlier, &#226;&#8364;&#339;Endogenous IFN-&#240;?&#8250;&#190; required resistance                cyclooxygenase released prostaglandin mediates immunosup- <br />       acute Trypanosoma cruzi infection mice,&#226;&#8364;? Journal                   pression acute phase experimental Trypanosoma cruzi <br />       Immunology, vol. 146, no. 10, pp. 3626&#226;&#8364;&#8220;3632, 1991.                          infection,&#226;&#8364;? Experimental Parasitology, vol. 111, no. 2, pp. 71&#226;&#8364;&#8220;79, <br />                                                                                   2005. <br />  [61] D. O. Adams T. A. Hamilton, &#226;&#8364;&#339;Molecular transduc- <br />       tional mechanisms IFN&#240;?&#8250;&#190; signals regulate <br />       macrophage development,&#226;&#8364;? Immunological Reviews, vol. 97, pp. <br />       5&#226;&#8364;&#8220;27, 1987. <br /> [62] Y. Kita, T. Takahashi, N. Uozumi, L. Nallan, M. H. Gelb, and <br />       T. Shimizu, &#226;&#8364;&#339;Pathway-oriented profiling lipid mediators in <br />       macrophages,&#226;&#8364;? Biochemical Biophysical Research Commu- <br />       nications, vol. 330, no. 3, pp. 898&#226;&#8364;&#8220;906, 2005. <br /> [63] Q. Wu, Y. Feng, Y. Yang et al., &#226;&#8364;&#339;Kinetics <span id='am-81' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-82' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-83' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-84' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-85' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-86' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-87' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-88' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-89' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-90' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-91' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-92' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-93' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-94' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-95' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-96' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-97' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-98' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-99' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-100' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-101' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-102' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-103' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-104' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-105' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-106' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-107' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-108' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-109' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-110' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-111' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-112' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-113' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-114' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-115' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-116' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-117' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-118' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-119' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-120' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-121' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-122' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-123' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-124' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-125' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-126' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-127' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-128' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-129' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-130' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-131' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-132' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-133' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-134' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-135' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-136' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-137' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-138' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-139' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-140' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-141' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-142' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-143' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-144' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-145' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-146' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-147' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-148' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-149' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-150' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-151' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-152' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-153' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-154' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-155' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-156' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-157' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-158' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span>phenotype</span> <br /> </body></html>